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ABSTRACT 
People with psychotic disorders have an increased risk of obesity, 
cardiovascular disease and diabetes. There is also a pro-inflammatory 
activation associated with psychotic disorders which may increase 
cardiovascular risk. The mortality of people with psychotic disorders is 
increased, reducing the average lifespan by 15-20 years. However, people 
with first-episode psychosis (FEP) are generally physically healthy at the 
onset of the first psychotic episode, and the longitudinal development of low-
grade inflammation in psychosis is largely unknown. 
This study aimed to examine anthropometric (weight, waist 
circumference) and metabolic parameters in people with FEP at treatment 
onset and during a one-year follow-up. Predictors of weight gain and increase 
of waist circumference were investigated in FEP. The relationship between 
changes in anthropometric measures and low-grade inflammation was 
analysed. Weight, waist circumference and laboratory parameters, including 
a high-sensitivity assay of the inflammatory marker C-reactive protein (hs-
CRP), glucose and lipid levels, were measured at study baseline, and at two 
and 12 months. At baseline, patients with FEP were compared to healthy, 
age, gender and region of residence matched controls. The longitudinal 
changes in anthropometric and laboratory parameters were examined within 
the group with FEP. 
Another aim of the study was to investigate mortality and factors 
associated with mortality risk in psychotic disorders in Finland. The 
mortality in the Health 2000 population sample of 5642 Finns aged 30-70 
years, including 106 patients with non-affective psychosis (NAP), was 
analysed with information on mortality and causes of death during a 13-year 
follow-up period. 
People with FEP and healthy controls had similar body mass index, waist 
circumference, hs-CRP and fasting glucose at study baseline. However, 
people with FEP had higher total and low-density lipoprotein (LDL) 
cholesterol, triglyceride, insulin and insulin resistance levels at baseline. The 
median weight gain in FEP patients at the 12-month assessment was 9.6kg 
and increase of waist circumference 6.0cm. Insulin resistance and olanzapine 
medication at baseline predicted more weight gain during the 12-month 
follow-up in FEP. In addition, baseline insulin resistance predicted increase 
in waist circumference. A significant, over 2.5-fold increase was observed in 
hs-CRP during the follow-up in FEP. The hs-CRP levels were predicted by 
waist circumference and female gender in mixed-effects regression analysis. 
The all-cause mortality hazard ratio (HR) adjusted for age and gender in 
NAP was 2.99, and the HR for mortality from natural causes 2.81. The all-
cause mortality HR was reduced to 2.11 and natural cause HR to 1.98 when 
adjusted for socioeconomic factors, smoking, body mass index, chronic 
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physical disease and inflammation. Antipsychotic medication use was 
associated with lower natural cause mortality risk, and smoking with 
increased natural cause mortality risk in people with NAP. 
In this study, people with FEP had a significant increase in body weight, 
waist circumference and low-grade inflammation during the first year of 
treatment of the psychotic disorder. Insulin resistance early in the treatment 
of FEP may be a marker for vulnerability for weight gain and abdominal 
obesity. The low-grade inflammation was strongly related to the increase in 
abdominal adiposity, suggesting that hs-CRP is primarily a marker of 
metabolic risk in FEP. Olanzapine was the most commonly prescribed 
antipsychotic in FEP despite the high risk for the associated weight gain. 
Antipsychotics with less weight gain potential should be considered as first-
line treatment in FEP. Smoking cessation should be promoted in people with 
psychotic disorders to reduce excess mortality. The excess mortality in NAP 
was not completely explained by socioeconomic or lifestyle factors nor by 
chronic physical disease. There may be factors associated with quality of 
treatment of physical disease in NAP explaining part of the premature 







Psykoottisiin häiriöihin liittyy kohonnut lihavuuden, sydän- ja 
verisuonisairauksien ja diabeteksen riski. Lisäksi psykoottisiin häiriöihin on 
todettu liittyvän matala-asteinen tulehdus, joka nostaa sydän- ja 
verisuonisairauksien riskiä. Psykoosisairauksia sairastavien riski 
ennenaikaiseen kuolleisuuteen on muuta väestöä suurempi,  ja heidän 
keskimääräinen elinikänsä on 15-20 vuotta muuta väestöä lyhyempi. 
Ensimmäistä kertaa psykoosiin sairastuneet ovat kuitenkin yleensä fyysisesti 
terveitä, eikä matala-asteisen tulehduksen kehittymistä ensipsykoosin 
yhteydessä ole juurikaan tutkittu pitkittäisasetelmissa. 
Tämän tutkimuksen tavoitteena oli tutkia ensimmäistä kertaa psykoosiin 
sairastuneiden painoa, vyötärönympärystä sekä rasva- ja 
sokeriaineenvaihduntaa psykoosin hoidon alkaessa ja ensimmäisen 
hoitovuoden aikana. Tutkimuksessa selvitettiin painonnousun ja 
vyötärönympäryksen muutoksen ennustajia. Lisäksi tutkittiin painon ja 
vyötärönympäryksen yhteyttä matala-asteisen tulehduksen kehittymiseen. 
Paino, vyötärönympärys ja laboratoriomittaukset, kuten matala-asteisesta 
tulehduksesta kertova herkkä C-reaktiivisen proteiinin määritys (CRP), veren 
glukoosi ja rasva-arvot, mitattiin tutkimuksen alkaessa sekä lisäksi kahden ja 
kahdentoista kuukauden kohdalla. Tutkimuksen alkaessa ensimmäistä 
kertaa psykoosiin sairastuneita verrattiin terveisiin, iän, sukupuolen ja 
asuinalueen mukaan kaltaistettuihin verrokkihenkilöihin. Lisäksi tutkittiin 
seuranta-aikana ensipsykoosiryhmässä havaittuja muutoksia painossa, 
vyötärönympäryksessä ja laboratorioarvoissa. 
Tutkimuksen toinen tavoite oli selvittää psykoottisiin häiriöihin liittyvää 
kuolleisuutta ja siihen liittyviä tekijöitä Suomessa. Kuolleisuutta ja 
kuolinsyitä tutkittiin Terveys 2000 -aineiston 5642 30-70-vuotiaan 
suomalaisen ja otokseen sisältyvän 106:n ei-affektiivista psykoottista häiriötä 
sairastavan joukossa 13 vuoden aikana. 
Tutkimuksen alkaessa ensipsykoosiryhmän ja verrokkihenkilöiden välillä 
ei ollut eroja painoindeksissä, vyötärönympäryksessä, herkässä CRP-
määrityksessä tai paastoglukoosissa. Ensipsykoosiryhmässä todettiin 
tutkimuksen alussa korkeampi kokonais- ja LDL-kolesteroli-, triglyseridi- ja 
insuliinipitoisuus sekä insuliiniresistenssi. Ensipsykoosiryhmässä 
painonnousu 12 kuukauden seurannan aikana oli 9,6 kg (mediaani) ja 
vyötärönympäryksen kasvu 6,0 cm. Insuliiniresistenssi ja 
olantsapiinilääkitys tutkimuksen alkaessa ennustivat suurempaa 
painonnousua 12 kuukauden aikana. Insuliiniresistenssi ennusti lisäksi 
vyötärönympäryksen kasvua. Herkässä CRP:ssä havaittiin seurannan aikana 
2,5-kertainen nousu ensipsykoosiryhmässä. Vyötärönympärys ja 
naissukupuoli ennustivat herkän CRP:n pitoisuutta. 
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Kuolleisuus oli ei-affektiivisissa psykoottisissa häiriöissä selvästi 
korkeampi kuin tutkimusväestössä keskimäärin; kokonaiskuolleisuuden 
riskisuhde ikä ja sukupuoli vakioituna oli 2,99. Luonnollisten kuolinsyiden 
osalta riskisuhde oli 2,81. Kun otettiin huomioon sosioekonomiset tekijät, 
tupakointi, painoindeksi, krooniset fyysiset sairaudet ja tulehdus, 
kokonaiskuolleisuuden riskisuhde oli 2,11 ja tautikuolleisuuden osalta 1,98. 
Psykoosilääkityksen käyttö oli yhteydessä matalampaan tautikuolleisuuteen, 
tupakointi puolestaan lisäsi riskiä.  
Tutkimuksessa todettiin, että ensimmäistä kertaa psykoosiin 
sairastuneiden paino nousee ja vyötärönympärys kasvaa merkittävästi 
ensimmäisen psykoosin hoitovuoden aikana ja että tähän liittyy matala-
asteisen tulehduksen kehittyminen. Ensipsykoosin hoidon alussa todettu 
insuliiniresistenssi voi olla painonnousun ja vyötärölihavuuden kehittymisen 
riskitekijä. Matala-asteinen tulehdus oli vahvasti yhteydessä 
vyötärölihavuuteen, mikä viittaa siihen, että herkän CRP:n pitoisuus kertoo 
metabolisesta riskistä ensipsykoosissa. Olantsapiini oli yleisimmin määrätty 
psykoosilääke ensipsykoosiryhmässä, vaikka lääkkeen käyttöön liittyy suurin 
painonnousun riski. Ensisijaiseksi lääkitykseksi ensimmäisessä psykoosissa 
tulisi harkita psykoosilääkkeitä, joihin liittyy vähäisempi painonnousun riski. 
Psykoottisista häiriöistä kärsiviä tulisi tukea tupakoinnin lopettamiseen 
häiriöihin liittyvän korkean kuolleisuuden vähentämiseksi. Korkeampi 
kuolleisuus ei-affektiivisissa psykooseissa ei selittynyt kokonaan 
sosioekonomisilla tekijöillä, elintavoilla tai fyysisillä sairauksilla. 
Ennenaikaisen kuolleisuuden taustalla voi olla tekijöitä, jotka liittyvät 
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Psychotic disorders are complex and serious mental disorders with varying 
course and prognosis. In Finland, approximately 3% of the population is 
affected by a psychotic disorder at some point in their life (Perälä et al., 
2007). The majority of people with a psychotic disorder have an episodic 
course of illness, with over a half experiencing remission during five years 
after the first episode, and over a third recovering (Lally et al., 2017). 
However, about a fifth do not respond to antipsychotic treatment from illness 
onset (Demjaha et al., 2017), and only a minority with a more chronic course 
of psychotic illness recover (Jääskeläinen et al., 2013). 
The mortality in chronic psychotic disorders is substantially increased, 
resulting in life expectancies 15-20 years shorter than in the general 
population (Laursen et al., 2014). The excess premature mortality is mostly 
due to chronic physical disease, such as cancer, cardiovascular and 
respiratory disease (Olfson et al., 2015). People with psychotic disorders have 
an increased risk for metabolic syndrome (MetS) and type 2 diabetes (T2D) 
(Mitchell et al., 2013b; Suvisaari et al., 2016). Suicides account for most of 
the excess mortality during the early course of psychotic illness (Simon et al., 
2018) and, overall, lifetime suicide risk in schizophrenia is approximately 5% 
(Palmer et al., 2005). 
The mortality gap between the lower life expectancy of people with 
serious mental illness (SMI, i.e. severe major depression, bipolar disorder, 
and schizophrenia and related psychoses) and the general population has not 
narrowed in recent decades. In fact, some studies have shown that the 
mortality gap has widened despite the progress in the diagnostics and 
treatment of cardiovascular disease and cancer (Lumme et al., 2016; 
Manderbacka et al., 2017; Osby et al., 2016). 
The onset of psychosis is usually in adolescence or early adulthood, when 
the affected individuals are generally physically healthy. Although there is 
evidence that people with first-episode psychosis (FEP) differ from their 
healthy peers in terms of lipid levels and glucose metabolism (Misiak et al., 
2017; Pillinger et al., 2017b, 2017a), antipsychotic medication has a strong 
propensity to cause weight gain (Bak et al., 2014; Leucht et al., 2013). 
Antipsychotics also have a detrimental effect on lipid and glucose 
metabolism (Meyer and Koro, 2004; Newcomer, 2005). These adverse 
effects of antipsychotics are associated with an increased risk of several 
physical diseases (Correll et al., 2015). Psychotic illness is also associated 
with smoking, poor diet and low level of physical activity, which further 
undermines the physical health of patients (De Leon and Diaz, 2005; 
Dipasquale et al., 2013; Stubbs et al., 2016).  
Different risk factors for weight gain and metabolic changes in FEP, such 
as young age and low premorbid body mass index (BMI), have been 
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identified but with limited consistency (Perez-Iglesias et al., 2014; Strassnig 
et al., 2007). Early recognition of patients with the greatest risk for harmful 
metabolic changes would offer a way to prevent physical comorbidity in 
psychotic disorders, and thus help to reduce the excess mortality in SMI. 
Low-grade inflammation is associated with obesity and increased all-
cause mortality in the general population (Choi et al., 2013; Ridker, 2016). 
Meta-analytic evidence implies that C-reactive protein (CRP) is increased in 
schizophrenia and related chronic psychotic disorders (Fernandes et al., 
2016). Whether increased CRP is inherently connected with the disease 
process of psychotic disorders or reflects the increase in weight and 
abdominal obesity, it would nonetheless be of great importance to identify 
factors that drive the development of pro-inflammatory activation in FEP. 
The aim of this thesis was to investigate longitudinal changes in weight, 
waist circumference, metabolic parameters related to glucose and lipids and 
low-grade inflammation, as measured by high-sensitivity CRP assay (hs-
CRP), in FEP during the first year of treatment. Additionally, mortality in 
non-affective psychosis (NAP) was investigated to examine the extent of 
increased mortality in this group of people in Finland, and to find factors 





2 REVIEW OF THE LITERATURE 
2.1 WHAT ARE PSYCHOTIC DISORDERS? 
Psychosis is characterized by a distorted sense of reality. Psychotic symptoms 
include hallucinations, delusions, negative symptoms (i.e. flattening of 
emotions, lack of motivational drive, social withdrawal and reduced motor 
activity), symptoms of disorganization (e.g. incoherent speech or behaviour) 
and catatonic symptoms (characterized by extreme psychomotor 
retardation/immobility or excitation/hyperactivity). Cognitive impairment 
and disturbances in mood (manic and depressive symptoms) also constitute 
dimensions of symptoms in psychotic disorders (van Os and Kapur, 2009). 
The mental disorders with psychotic symptoms as the most prominent 
feature are classified as psychotic disorders. However, psychotic symptoms 
are not present exclusively in psychotic disorders, as mood disorders may 
also present with psychotic symptoms. 
The current view is that none of the psychotic symptoms are 
“pathognomonic”, i.e. specific to a particular psychotic disorder. Psychotic 
disorders, like all other psychiatric disorders, are syndromes, defined by 
constellations of symptoms of certain durations. Historically, attempts have 
been made to categorize hallucinations and delusions by their quality and 
content. The Schneiderian first-rank symptoms (named after the German 
psychiatrist Kurt Schneider, 1887-1967) are, depending on the classification 
system, still used to define the typical psychotic symptoms of schizophrenia 
(Carpenter et al., 1973). These first-rank symptoms include hallucinations, 
such as voices conversing with each other or commenting on the person’s 
behaviour, experiences of thought withdrawal (thoughts being removed from 
the mind), thought insertion (thoughts being inserted into the person’s mind 
by an external agent), thought broadcasting (person’s thoughts are made 
observable by others) and made feelings and actions (feelings, impulses and 
actions sensed as imposed by an external agent). However, the specificity of 
first-rank symptoms for schizophrenia has been questioned and the 
symptoms were removed from the latest diagnostic manual, the DSM-5, as 
they may also be present in other psychotic disorders (Ihara et al., 2009). 
Similarly, lack of insight, although common in acute psychosis and a 
predictor of poor outcome (Novick et al., 2015), is not a prerequisite for a 
diagnosis of a psychotic disorder. 
A dichotomous distinction between psychotic and non-psychotic states 
may be an artificial categorization, as psychotic experiences exist on a 
continuum and are relatively common in the general population (Van Os et 
al., 2009). Most of the psychotic experiences in the population are transitory 
and do not involve significant distress. The risk of transitioning to a more 
persistent state of psychotic symptoms and further to a psychiatric disorder 
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depends on the individual’s genetic risk and environmental factors (Van Os 
et al., 2009).  
The variation in the course, duration and severity of psychotic disorders is 
substantial. The duration of psychotic disorders ranges from a brief episode, 
measured in days, to a chronic illness that persists for decades. Illness onset 
can be gradual, with a clear phase of prodromal symptoms, including, e.g. 
symptoms of depression and anxiety, and a decline in daily functioning 
before the onset of psychosis, or the onset can be sudden with a rapid shift to 
psychosis. Similar variation applies for recovery, ranging from a fast 
recuperation with a return of the premorbid level of functioning to a 
persisting state of symptoms interfering constantly with daily life.  
According to a meta-analysis, 38% of individuals with FEP experienced 
long-standing absence of symptoms and good level of functioning after the 
first psychotic episode during an average follow-up of seven years (Lally et 
al., 2017). However, a significant proportion of individuals with FEP have 
recurrent episodes with unfavourable consequences on the ability to achieve 
goals in life and physical health. Psychotic disorders are one of the gravest 
mental disorders, as measured by subjective experience, premature mortality 
and economic costs to the individual and society. Schizophrenia, which is the 
most common of psychotic disorders, has been estimated to encompass a 
significant health burden, as measured by disability-adjusted life years 
(DALYs). DALYs combines excess mortality (life years lost due to premature 
death) and the chronicity of the disorder (years lived with disability). 
Schizophrenia was the 8th leading cause of DALYs globally among people 
aged 15-44 years in a 2001 World Health Report (World Health 
Organization, 2001). Furthermore, taking into account the relative rarity of 
psychotic disorders, the direct and indirect economic costs of psychotic 
disorders are perhaps greater than in any other psychiatric disorder (Rössler 
et al., 2005).  
 
2.2 DIAGNOSTIC CLASSIFICATION OF PSYCHOTIC 
DISORDERS 
The classification systems currently in use in psychiatry are the DSM-5 
(Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) 
published by the American Psychiatrist Association in 2013 (American 
Psychiatric Association, 2013) and the International Classification of 
Diseases, Tenth Edition (ICD-10) Classification of Mental and Behavioural 
Disorders published by the World Health Organization (WHO) (World 
Health Organization, 1992). While ICD-10 criteria are used in most countries 
of the world, DSM-5, which is the official classification system in the United 
States, dominates in psychiatric research (Tyrer, 2014). The predecessor of 
DSM-5 was the DSM-IV-TR (Diagnostic and Statistical Manual of Mental 
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Disorders, Fourth Edition, Text Revision), published in 2000 (American 
Psychiatric Association, 2000). In the following paragraphs, the diagnostic 
criteria of the major psychotic disorders in DSM-IV-TR, DSM-5 and ICD-10 
are compared. 
2.2.1 SCHIZOPHRENIA 
The comparison of DSM-IV-TR, DSM-5 and ICD-10 criteria for 
schizophrenia is presented in Table 1. A major difference in the criteria is 
that DSM-IV-TR and DSM-5 require a minimum total duration of illness of 6 
months with at least 1 month of active symptoms, while ICD-10 requires only 
1-month total duration of the illness. Further differences are that DSM-IV-
TR required only one psychotic symptom in Criterion A if the delusions were 
bizarre, or if the hallucinations consisted of a running commentary of the 
person’s behaviour or thoughts or voices conversing with each other. This 
criterion reflected the Schneiderian first-rank symptoms of schizophrenia, 
and was removed from the DSM-5, leading to the requirement of two 
Criterion A symptoms for the diagnosis of schizophrenia. DSM-IV-TR and 
DSM-5 require deterioration in the level of social and occupational 
functioning, while ICD-10 does not. All the schizophrenia subtypes were 
eliminated from DSM-5. ICD-10 includes a diagnosis of simple schizophrenia 
which is diagnosed in the absence of positive symptoms, while the equivalent 
“Residual type” in DSM-IV-TR was removed from DSM-5.  
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Table 1. Comparison of ICD-10, DSM-IV-TR and DSM-5 diagnostic criteria for schizophrenia 
 ICD-10 DSM-IV-TR DSM-5 
 G1:  
1) At least one of the 
following 





b) Delusions of 
control, influence 
or passivity, clearly 
referred to 









person’s behaviour, or 
discussing about the 
person, or voices 
coming from some 
part of the body  
d) Persistent delusions 




2) Or at least two of 
the following: 
e) Persistent 
hallucinations in any 
modality, every day at 




g) Catatonic behaviour 
h) Negative symptoms 
A: Two or more* of the 
following present for a 
significant portion of time 
over a 1-month period (or 











A: Two or more of the 
same symptoms as in 
DSM-IV-TR. One of 
these must be 1, 2 or 3. 
 G2: Most commonly 
used exclusion 
criteria: If the patient 
meets the criteria for 
manic or depressive 
episode, the criteria 
listed above must have 
been met before the 
onset of the mood 
disorder 
B: Since the onset of the 
disorder, at least one major 
area of functioning (work, 
social relations, self-care) is 
below the level achieved 
prior to the onset for a 
significant portion of time 





Table 1. (continued) 
 ICD-10 DSM-IV-TR DSM-5 
 G3: The disorder is 
not attributable to 
organic brain disease, 




C: Continuous signs of the 
disturbance for at least 6 
months (must include at 
least one month, or less if 
successfully treated, 
symptoms meeting 
Criterion A, and may 
include periods of 
prodromal/residual 
symptoms) 
C: As in DSM-IV-TR 
  D: Schizoaffective disorder 
and mood disorder with 
psychotic features have 
been excluded 
D: As in DSM-IV-TR, 
considering the revised 
criteria for 
schizoaffective 
disorder in DSM-5 
  E: The disorder is not due 
to the direct physiological 
effect of a substance or a 
general medical condition 
E: As in DSM-IV-TR 
  F: If there is history of 
autistic disorder or another 
pervasive developmental 
disorder, the diagnosis of 
schizophrenia is made only 
if prominent delusions or 
hallucinations are also 
present ≥ 1 month 




disorder of childhood 
onset, the diagnosis of 
schizophrenia is made 
only if prominent 
delusions or 
hallucinations are also 
present ≥ 1 month 
*Only one is required if delusions are bizarre, or hallucinations consist of a running commentary on 
the person’s behaviour or thoughts, or voices conversing with each other 
DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; 
DSM-5, Diagnostic and Statistical Manual of Mental Disorders, 5th Edition; ICD-10, International 
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2.2.2 BRIEF PSYCHOTIC DISORDER 
According to DSM-IV-TR and DSM-5, brief psychotic disorder has a sudden 
onset of psychotic symptoms that last at least 1 day but less than 1 month. 
The psychotic symptoms required are the same as in Criterion A for 
schizophrenia, except for negative symptoms which are not included in brief 
psychotic disorder. After full remission of the symptoms within the 1-month 
duration of the disorder, patients regain the level of function they had before 
the onset of the disorder.  
Similar to brief psychotic disorder, ICD-10 defines an acute and transient 
psychotic disorder (with delusions, hallucinations or incoherent speech) with 
onset within 2 weeks and full remission within 1-3 months. Those who meet 
the criteria for ICD-10’s acute and transient psychotic disorders fall under 
many different categories in DSM-IV-TR or DSM-5, including brief psychotic 
disorder, schizophreniform disorder and psychotic disorder not otherwise 
specified. 
2.2.3 SCHIZOPHRENIFORM DISORDER 
Both DSM-IV-TR and DSM-5 define schizophreniform disorder similarly. 
The Criterion A is the same as for schizophrenia, except that the total 
duration of the illness in schizophreniform disorder is 1-6 months (including 
prodromal, active and residual symptoms). Although there may also be 
disturbed functioning in work or social relations in schizophreniform 
disorder, it is not required in DSM-IV-TR or in DSM-5. The disturbance does 
not meet the criteria for schizoaffective or mood disorder with psychotic 
features. 
ICD-10 does not include schizophreniform disorder. Many of those 
diagnosed with DSM schizophreniform disorder would be classified as 
having schizophrenia according to ICD-10. An acute schizophrenia-like 
psychotic disorder can be diagnosed according to ICD-10 if the criteria for 
schizophrenia are met, and the onset of symptoms is rapid (within 2 weeks), 
but the duration is shorter than the 1 month required for schizophrenia. 
2.2.4 SCHIZOAFFECTIVE DISORDER 
DSM-IV-TR states that an essential feature of schizoaffective disorder is an 
uninterrupted period of illness with a major depressive, manic or mixed 
episode concurrent with symptoms that meet Criterion A for schizophrenia. 
Also, during the same period of illness, there has been a 2-week period with 
delusions or hallucinations but without prominent mood symptoms. It is also 
required that mood episodes are present for a substantial portion of the total 
duration of the active and residual periods of the illness. 
DSM-5 specifies that delusions or hallucinations must have been present 
for at least 2 weeks in the absence of a mood episode during the lifetime 
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duration of the illness, and that the mood episodes are present for the 
majority of the total duration of the active and residual phase of the illness. 
In ICD-10, schizoaffective disorder is defined as a concurrent mood 
episode of at least moderate severity, with psychotic symptoms similar to 
schizophrenia, present at least 2 weeks. The mood episode and psychotic 
symptoms must coincide “for at least some time of the episode”, and both 
must be prominent in the clinical picture. ICD-10 also requires a balance 
between the number, severity and duration of the affective and psychotic 
symptoms. 
2.2.5 DELUSIONAL DISORDER 
In DSM-IV-TR’s definition of delusional disorder, non-bizarre delusions are 
required to persist for at least 1 month. Hallucinations may be present but 
not prominent. Ability to function is generally preserved and behaviour is not 
markedly odd or bizarre. Brief mood episode can co-occur with delusions but 
their duration has to be short relative to the duration of the delusional 
periods. 
DSM-5 is identical to DSM-IV-TR in the definition of delusional disorder, 
except that DSM-5 does not require that the delusions are non-bizarre. 
ICD-10 states that the delusions have to be other than those listed as 
typical schizophrenic delusions and they must have been present for at least 
3 months. Persistent hallucinations in any modality are not allowed, but 
occasional auditory hallucinations are possible if they are not those listed for 
typical schizophrenic hallucinations. 
2.2.6 SUBSTANCE-INDUCED PSYCHOTIC DISORDER 
According to DSM-IV-TR and DSM-5, substance or medication-induced 
psychotic disorder is diagnosed when delusions or hallucinations have 
developed soon after use or withdrawal of a substance that is capable of 
inducing such symptoms, and the disorder is not better explained by an 
independent psychotic disorder. DSM-IV-TR and DSM-5 specify that the 
hallucinations and delusions must not be recognized by the individual as 
substance induced. 
Similarly, in ICD-10 psychotic disorder due to psychoactive substance use 
is diagnosed when psychotic symptoms occur during or immediately after 
substance use (usually in 48 hours, but a late-onset psychotic disorder with 
onset more than 2 weeks after substance use can be diagnosed as well). The 
disorder resolves at least partially in 1 month and fully in 6 months.  
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2.2.7 PSYCHOTIC DISORDER DUE TO ANOTHER MEDICAL 
CONDITION 
The definitions of DSM-IV-TR and DSM-5 of psychotic disorder due to 
another medical condition are identical: they require prominent 
hallucinations or delusions with evidence that the symptoms are the direct 
physiological consequence of a medical condition, and the disturbance is not 
better accounted for by another mental disorder.  
ICD-10 divides the category of “other mental disorders due to brain 
damage and dysfunction and to physical disease” into organic hallucinosis, 
with persistent or recurrent hallucinations, and organic delusional 
(schizophrenia-like) disorder, characterized by recurrent delusions. 
2.2.8 PSYCHOTIC DISORDER NOT OTHERWISE SPECIFIED 
According to DSM-IV-TR, psychotic disorder not otherwise specified (NOS) 
is diagnosed if psychotic symptoms are present but there is inadequate or 
contradictory information to make a specific diagnosis, or symptoms do not 
meet the criteria for any specific psychotic disorder. 
DSM-5 splits psychotic disorder NOS into the categories of “other 
specified schizophrenia spectrum and other psychotic disorder” and 
“unspecified schizophrenia spectrum and other psychotic disorder”. The 
former category applies to situations where the symptoms do not meet full 
criteria for any specific psychotic disorders, and the latter for situations 
where information for making a specific diagnosis is inadequate. 
According to ICD-10, a diagnosis of other non-organic psychotic disorder 
is made when the psychotic symptoms do not meet the criteria for any 
specific psychotic disorder. ICD-10 also lists a diagnosis of unspecified non-
organic psychosis. 
2.2.9 BIPOLAR DISORDERS 
In DSM-IV-TR, bipolar I and II disorders were listed under the heading of 
mood disorders, while in DSM-5 the disorders were placed under a separate 
heading of Bipolar and Related Disorders to better recognize that bipolar 
disorders share common genetic factors and symptoms with both mood 
disorders and psychotic disorders. Bipolar disorders are characterized by 
recurrent depressive and manic or hypomanic episodes. DSM-IV-TR and 
DSM-5 require one or more manic episodes for a diagnosis of bipolar I 
disorder, while a diagnosis of bipolar II disorder requires at least one 
hypomanic episode. The definition of a mixed episode was eliminated from 
DSM-5; instead a depressive episode can be diagnosed with a specifier “with 
mixed features”. ICD-10 requires at least two mood episodes, of which at 
least one has to be a hypomanic, manic or mixed episode, for a diagnosis of 
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bipolar disorder. Psychotic symptoms can occur in manic and depressive 
episodes. 
2.2.10 MAJOR DEPRESSIVE DISORDER WITH PSYCHOTIC 
FEATURES 
In DSM-IV-TR, DSM-5 and ICD-10, major depressive disorder with 
psychotic features (or severe depressive episode with psychotic symptoms in 
ICD-10) is diagnosed when psychotic symptoms (delusions or hallucinations) 
are present during a major depressive disorder. 
2.3 PREVALENCE AND INCIDENCE OF PSYCHOTIC 
DISORDERS 
Prevalence and incidence are measures used in epidemiological research to 
describe how many persons at risk in a certain population are affected by a 
disease. Prevalence is reported as the ratio of affected persons per 100 or 
1000 persons in the population. Prevalence can be measured as point 
prevalence, giving an estimate of the prevalence at a given time, or as 
prevalence over a certain period. Incidence is a measure of new cases in a 
population at risk over a given period.  
The lifetime prevalence of DSM-IV schizophrenia in the Finnish Health 
2000 study among persons aged over 30 years was 0.87 % (Perälä et al., 
2007). A systematic review of prevalence studies conducted in 46 countries 
reported a 0.40% lifetime prevalence of schizophrenia without a statistical 
significant difference in the prevalence between males and females (Saha et 
al., 2005). The prevalence estimates were higher in migrant groups 
compared to native population (Saha et al., 2005). Other psychotic disorders 
have somewhat lower prevalence estimates compared to schizophrenia: in 
the aforementioned study by Perälä et al., the prevalence was 0.32% for 
schizoaffective disorder, 0.07% for schizophreniform disorder, 0.18% for 
delusional disorder, 0.05% for brief psychotic disorder, 0.45 for psychotic 
disorder NOS, 0.24% for bipolar I disorder, 0.35% for major 
depressive disorder with psychotic features, 0.42% for substance-
induced psychotic disorders and 0.21% for psychotic disorders due to 
a general medical condition (Perälä et al., 2007). 
A systematic review yielded a median incidence rate of schizophrenia of 
15.2 per 100,000 with males having an increased rate compared to females 
(median rate ratio 1.40) (McGrath et al., 2004). Urbanicity was associated 
with higher incidence rate, as well as migrant status (McGrath et al., 2004). 
The incidence rate is at its highest among men aged 20-24 years and in 
women aged 25-29, although for women an increase in the incidence after 
age 40 is observed. Similar findings of lower age of onset in males compared 
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to females and declining incidence with increasing age has also been 
observed in other psychoses (Sutterland et al., 2013). 
A systematic review of incidence studies conducted in England between 
1950-2009 reported a higher incidence rate for non-affective psychoses than 
affective psychoses (23.2/100,000 person years vs. 12.4/100,000 person 
years) (Kirkbride et al., 2012). The incidence rates for non-affective 
psychoses declined with age, and women had another peak in the rate in mid 
to late 40s. In affective psychoses, women had higher incidence rates after 
the age of 45 than men, but before that there were no statistically significant 
gender differences (Kirkbride et al., 2012). 
2.4 PHARMACOLOGICAL TREATMENT OF PSYCHOTIC 
DISORDERS 
Antipsychotic medication is the mainstay of the treatment of psychotic 
disorders with well-established evidence of efficacy in reducing psychotic 
symptoms and preventing relapse (Leucht et al., 2011). The first 
antipsychotic agent, chlorpromazine, was discovered by a French surgeon 
Henri Laborit in a serendipitous manner. He administered chlorpromazine 
to patients undergoing surgery and observed that the drug made patients less 
anxious without a significant decrease in the level of consciousness. The 
effects of the newly discovered drug were tested by Laborit’s colleagues on 
patients with agitation and hallucinations with dramatic effects. The drug 
reduced psychotic symptoms and anxiety, a finding that marked a significant 
advancement in the treatment of chronically ill patients with psychotic 
disorders, for whom effective treatment methods were practically non-
existent at the time (Ban, 2007). 
After the discovery of chlorpromazine, similar molecules were developed, 
such as thioridazine and fluphenazine, belonging to the same molecule class 
of phenothiazines as chlorpromazine. Drugs belonging to other chemical 
classes, such as haloperidol (butyrophenones) and zuclopenthixol 
(thioxanthenes), were also developed, but their effectiveness was essentially 
the same as chlorpromazine, although adverse effects differed. In 1958, a 
Swiss pharmaceutical company developed clozapine, which was later found 
to have superior effectiveness in reducing psychotic symptoms resistant to 
other antipsychotics. Clozapine was tested during the 1960s and released on 
to the market in the early 1970s. However, due to the finding that clozapine 
caused severe cases of agranulocytosis (Idänpään-Heikkilä et al., 1975), the 
drug was withdrawn. In 1990, after studies showing that clozapine was 
superior to other antipsychotics in reducing psychotic symptoms resistant to 
other drugs, clozapine was reinstated (Kane and Correll, 2010).  
In the 1990s, new antipsychotic agents that were classified as second-
generation antipsychotics (SGA), or atypical antipsychotics, were developed. 
Correspondingly, antipsychotics that were developed before the return of 
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clozapine in the 1990s were now categorized as first-generation (FGA), also 
referred to as typical or conventional antipsychotics in the literature. 
Originally, it was thought that the categories of different generations of 
antipsychotics would be based on differences in receptor binding affinities, 
but in fact the division has no clear-cut pharmacological boundaries, as both 
generations of antipsychotics have similar pharmacological actions.  
FGA in general have high affinity for the dopamine D2 receptor. D2 
antagonism is the main antipsychotic mechanism of action of FGA, which 
can be divided into high-potency and low-potency drugs by their affinity for 
the D2 receptor. A distinction between FGA and SGA is their differing 
propensity to cause extrapyramidal symptoms (EPS) such as rigidity, tremor 
and movement disorders (Meltzer, 2013). SGA generally cause less EPS than 
FGA. In particular, high-potency FGA cause significant EPS (Miyamoto et al., 
2005). The low-potency drugs, such as chlorpromazine, also have, in 
addition to the D2 antagonism, antagonistic effects on histamine, adrenergic 
and muscarinic receptors. These other receptor effects are associated with 
sedation, weight gain, orthostatic hypotension and anticholinergic effects, 
which are typical adverse effects for low-potency FGA. SGA in turn are also 
potent antagonists of the serotonin 5-HT2A receptors (Nasrallah, 2008). The 
5-HT2A receptor antagonism contributes to the antipsychotic action of the 
SGA and to the low risk of EPS (Meltzer, 2013). SGA target histamine, 
muscarinic and adrenergic receptors as well. These receptor actions are 
associated with the adverse effects of the SGA, but the significance for the 
antipsychotic effect is unclear (Meltzer, 2013). 
2.5 METABOLIC EFFECTS OF ANTIPSYCHOTICS 
Because antipsychotics target a multitude of receptors which are also 
involved in the central and peripheral energy metabolism and homeostasis, it 
is not surprising that antipsychotics also have extensive metabolic effects. 
Unfortunately, these metabolic effects, described in detail in the following 
paragraphs, are detrimental to health. They include weight gain, impaired 
glucose tolerance, dyslipidemia and an increased risk for MetS, T2D and 
cardiovascular complications. 
2.5.1 ANTIPSYCHOTIC-INDUCED WEIGHT GAIN 
 In the era of FGA, concern for the weight gain potential of antipsychotics 
was surpassed by the more acute adverse effects of the FGA such as EPS and 
increased prolactin levels. After the introduction of the SGA, awareness of 
the high prevalence of weight gain in people using antipsychotics increased. 
Weight gain affects a major percentage of people with psychotic disorders 
treated with antipsychotics, with proportion estimates ranging from 15% to 
72% (De Hert et al., 2011b). Weight gain is not only a physical risk factor, 
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contributing to the risk for dyslipidemia, diabetes, hypertension and other 
cardiovascular disease, but it is also a significant reason for non-adherence to 
drug treatment (Velligan et al., 2009). Antipsychotic-related weight gain is 
rapid during the first six to 12 months, and continues for at least the first 
three years of antipsychotic treatment (Bushe et al., 2012; Perez-Iglesias et 
al., 2014).  
Of the FGA, the low-potency antipsychotics (e.g. chlorpromazine) are 
more associated with higher average weight gain than high-potency 
antipsychotics (e.g. haloperidol) (De Hert et al., 2011c; Leucht et al., 2013). 
SGA, especially olanzapine and clozapine, are associated with the greatest 
weight gain of all antipsychotics (Leucht et al., 2013). Quetiapine, 
risperidone, paliperidone and sertindole are considered as having an 
intermediate propensity to cause weight gain, while aripiprazole and 
ziprasidone are generally associated with low risk for weight gain (De Hert et 
al., 2011c; Leucht et al., 2013). However, there is individual variation in the 
amount of weight gain, and none of the antipsychotics have been shown to be 
consistently weight neutral. In a meta-analysis, only haloperidol, aripiprazole 
and lurasidone were not associated with significantly more weight gain than 
placebo (Leucht et al., 2013). In another meta-analysis, aripiprazole, 
amisulpride and ziprasidone were deemed weight neutral (Bak et al., 2014). 
A meta-analysis investigating weight gain in first-episode psychosis found 
that only ziprasidone was not associated with increased risk of clinically 
significant weight gain (Tek et al., 2016). The average weight gain difference 
compared to placebo in first-episode psychosis was 3.22kg in the short-term 
(studies with <12 weeks of antipsychotic treatment) and the corresponding 
BMI change was 1.46kg/m2 (Tek et al., 2016). In the long-term (>12 weeks), 
the average weight gain was 5.30kg and BMI change 1.86kg/m2. 
Identifying reliable risk factors for antipsychotic-related weight gain 
would be useful to guide antipsychotic choice. There are a number of 
suggested risk factors, mediators and moderators for antipsychotic-related 
weight gain, but the findings have been inconsistent. Table 2 lists some of the 
findings of studies on antipsychotic-induced weight gain. Other suggested 
risk factors for weight gain, mentioned in a review, include family history of 
obesity and overeating as a stress response (De Hert et al., 2009). Young age 
and low pre-treatment BMI are the most consistently reported risk factors. 
However, these too have been questioned, as young age itself might not be a 
risk factor, but rather a proxy for less previous antipsychotic exposure 
(Correll et al., 2009). Moreover, the tendency for individuals with low pre-
treatment BMI to gain more weight might reflect a statistical artifact called 
regression to the mean, which means that extreme observations will tend to 
move closer to the mean of observations on the next measurement (Allison et 
al., 2009a). Taken together, from the clinical point of view, no single factor 
can be used to reliably identify individuals vulnerable to antipsychotic-





Table 2. Predictors of weight gain in psychosis 
Predictor Comments References 
Lower baseline 
BMI 
Low premorbid BMI has been 
associated with more weight gain. In 
Gebhardt et al. (2009) high premorbid 
BMI associated with more total BMI 
change and low premorbid BMI 
associated with higher acceleration of 
BMI change 
Basson et al., 2001; Kinon et 
al., 2001; Lee et al., 2011; 
Lipkovich et al., 2009; 
Neovius et al., 2007; 
Saddichha et al., 2008; 
Strassnig et al., 2007; Verma 
et al., 2009 
Young age Young patients have increased risk for 
weight gain 
Lee et al., 2011; Lipkovich et 
al., 2009; Safer, 2004; 
Strassnig et al., 2007; Verma 
et al., 2009 
Gender  Perez-Iglesias et al. found male gender 
to be associated with short-term (≤3 
months), but not long-term weight gain. 
Other studies have reported an 
association between female gender and 
more weight gain 
Gebhardt et al., 2009; Hakko 
et al., 2006; Homel et al., 
2002; Lee et al., 2011; 
Lipkovich et al., 2009; 
Neovius et al., 2007; Perez-
Iglesias et al., 2014; Verma 
et al., 2009 
Negative 
symptoms 
High level of negative symptoms 
associated with weight gain 
Strassnig et al., 2007 
Poor social 
functioning 
Poor social functioning associated with 
weigh gain 
Perez-Iglesias et al., 2014 
Schizophrenia 
subtype 
More weight gain in undifferentiated vs. 
paranoid subtype  




Polypharmacy associated with weight 
gain 
Strassnig et al., 2007 
Non-white ethnic 
background 
Weight gain associated with non-white 
ethnic background 
Basson et al., 2001; Chan et 
al., 2013; De Leon et al., 
2007; Krakowski et al., 
2009; Lipkovich et al., 2009; 
Stauffer et al., 2010 
 
Smoking Less weight gain in smokers Gebhardt et al., 2009 
Cannabis use Less weight gain and metabolic risk 
factors in cannabis users 
Bruins et al., 2016; Scheffler 
et al., 2018; Waterreus et al., 
2016 
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2.5.1.1 Physiological regulation of energy homeostasis, appetite and 
satiety 
The hypothalamic arcuate nucleus is a centre for appetite and satiety control, 
and contains two main cell types involved in maintaining energy 
homeostasis: orexigenic neuropeptide Y/Agouti-related peptide (NPY/AgRP) 
neurons and anorexigenic pro-opiomelanocortin (POMC) neurons (Manu et 
al., 2015). The hypothalamus receives signals from peripheral tissues by 
circulating metabolites (i.e. amino acids, fatty acids, glucose), hormones such 
as gut-related ghrelin, glucagon-like peptide 1 and peptide YY, and leptin and 
adiponectin produced by adipocytes (Skolnik and Ryan, 2014). Leptin’s main 
functions in maintaining energy homeostasis include appetite suppression 
and reducing insulin secretion. Production of leptin is directly proportionate 
to fat mass. In obesity, leptin resistance often develops, meaning that leptin 
loses its appetite suppressing and homeostasis maintaining effects (Skolnik 
and Ryan, 2014). Adiponectin is a hormone produced by adipocytes with 
decreasing levels in obesity. Adiponectin increases insulin sensitivity and 
glucose uptake to adipocytes (Nigro et al., 2014). 
Appetite and energy metabolism are not only regulated by these 
homeostatic mechanisms. Reward-dependent motivational mechanisms also 
determine eating behaviour. The pleasure obtained from eating foods with 
high energy content has helped people to survive in nutrient scarce 
environments. In modern society, with the abundance of energy-rich foods 
and daily activities requiring less physical activity than before, the reward 
mechanisms related to eating may have significant downsides, as they 
increase the craving for energy-rich foods (Chaput et al., 2011). The reward 
system involves dopaminergic mesocorticolimbic circuits arising from the 
ventral tegmental area and projecting to the nucleus accumbens, various 
other limbic areas, and to the prefrontal cortex (Arias-Carrián et al., 2010). 
There is interplay between the brain’s reward system and the hormones 
transmitting signals from peripheral energy metabolism. For example, leptin 
can inhibit the mesolimbic dopaminergic pathways and reduce food intake 
(Berthoud, 2012). In contrast, ghrelin may increase food intake by increasing 
the dopaminergic activity in ventral tegmental area and nucleus accumbens 
(Berthoud, 2012; Lenard and Berthoud, 2008). 
As reviewed by Mazier et al. (2015), another mechanism involved in 
regulating energy consumption and expenditure is the endocannabinoid 
system, which consists of the endocannabinoids and the centrally and 
peripherally located endocannabinoid receptors. N-
arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol are the 
most studied endocannabinoids. They act on CB1 and CB2 endocannabinoid 
receptors, which are found in several brain areas and peripheral organs. In 
the brain, endocannabinoid receptors in the hypothalamus and nucleus 
accumbens interact with orexigenic and anorexigenic signalling. The main 
function of the endocannabinoid system is to preserve and store energy: in 
the central nervous system, endocannabinoids increase food intake and 
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craving for palatable food, and also decrease centrally regulated energy 
expenditure and thermogenesis. Peripherally, endocannabinoids increase 
insulin secretion, lipogenesis and glucose uptake. In the gastrointestinal 
tract, endocannabinoids increase fat preference and intake by interacting 
with orexigenic mediators such as ghrelin (Mazier et al., 2015).  
2.5.1.2 How antipsychotics modify the regulation of energy 
homeostasis 
The potential mechanisms of antipsychotic-induced weight gain are complex 
and involve disturbance of energy homeostasis by disrupting the balance 
between caloric intake and energy expenditure. Antipsychotics increase the 
craving for food and suppress or delay satiety signalling which can lead to 
overeating (Correll et al., 2011). Antipsychotics have a variety of receptor 
targets, and many of these, including dopamine, serotonin and histamine 
receptor antagonism, are associated with weight gain. 
The main antipsychotic action of antipsychotic drugs is based on 
dopamine D2 antagonism. Antipsychotics with D2-specific receptor affinity, 
e.g. amisulpride, are also associated with weight gain, albeit to a lesser extent 
than antipsychotics with a wider array of receptor targets (Leucht et al., 
2013). In otherwise healthy individuals, obesity is associated with lower D2 
receptor density in the brain, possibly reflecting decreased activity in the 
reward pathways which may lead to increased food intake (Wang et al., 
2001). An interesting example of how dopamine antagonism can affect 
weight regulation comes from a study investigating the association of reward 
system activity, measured by functional magnetic resonance imaging during 
a monetary reward task, with amisulpride-related weight gain in people with 
schizophrenia (Nielsen et al., 2016). Weight gain in the study was predicted 
by lower striatal reward system activity before six-week treatment with 
amisulpride. Weight gain was also associated with increase in the reward 
system activity after treatment. The result suggests that reward deficiency 
may moderate the amount of weight gain associated with dopamine 
antagonism. 
Antagonism of the serotonin 5-HT2C receptor is associated with weight 
gain (Correll et al., 2011). Hypothalamic 5-HT2C receptors expressed by 
POMC neurons are crucial for serotonergic regulation of energy homeostasis 
(Xu et al., 2008). In animal studies, mice with deficient 5-HT2C receptors 
have disturbed regulation of feeding behaviour and are overweight (Tecott et 
al., 1995). Furthermore, pharmacological blockade of 5-HT2C receptors is 
also associated with increased feeding in animals (Correll et al., 2011). A 
putative mechanism by which serotonin antagonism increases food intake is 
the delayed onset of satiety signalling which can lead to increased meal sizes 
and binge eating (Correll et al., 2011). 
Antipsychotic antagonism on histamine H1 receptors is associated with 
weight gain (Kroeze et al., 2003), possibly by a leptin-dependent mechanism, 
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as mice with H1 receptor deficiency display leptin resistance (Masaki et al., 
2001). In addition, as reviewed by Correll et al. (2011), antagonism of the H1 
receptors in animal studies increases feeding. Another mechanism by which 
SGA may affect the regulation of food intake via H1 receptors is suggested by 
a mouse study, showing that by blocking H1 receptors SGA stimulate the 
hypothalamic adenosine monophosphate-activated protein kinase (AMP 
kinase) (Kim et al., 2007). The AMP kinase activity in the hypothalamus is 
under normal circumstances inhibited by leptin, producing leptin’s 
anorexigenic effect. Furthermore, this stimulation of AMP kinase by SGA, 
which overrides the effect of leptin, can be blocked by H1 receptor gene 
deletion in animal models (Kim et al., 2007).  
2.5.1.3 Influence of genetic variants in antipsychotic-related weight 
gain 
A meta-analysis, investigating genetic associations with antipsychotic 
medication-related weight gain, analysed 38 single nucleotide 
polymorphisms (SNPs) in 20 genes or genetic regions and found variations 
associated with weight gain in 9 genes (Zhang et al., 2016). The genetic 
variations most consistently associated with weight gain were located in 
genes that code for proteins which are also targets of antipsychotic drugs: 
serotonin 2C receptor (HTR2C), dopamine receptor D2 (DRD2) and alpha-
2A adrenergic receptor (ADRA2A). Other genes that were also associated 
with weight gain were the genes encoding for G protein subunit beta 3 
(GNB3), melanocortin 4 receptor (MC4R), brain-derived neurotrophic factor 
(BDNF) and insulin-induced gene 2 (INSIG2) (Zhang et al., 2016). 
HTR2C encodes the serotonin receptor 5-HT2C. The receptor has a role in 
appetite regulation and food intake (Vickers et al., 2003). Most atypical 
antipsychotics are potent antagonists of the receptor (Markowitz et al., 1999). 
Mutation of HTR2C in animal models is associated with hyperphagia, obesity 
and increased insulin resistance (Nonogaki et al., 1998; Xu et al., 2008). By 
contrast, agonists of 5-HT2C receptor can cause weight loss by decreasing 
food intake (Smith et al., 2010).  
Dopamine receptor D2, encoded by DRD2, is the main target of 
antipsychotics. Variation in the DRD2 gene has been linked with clinical 
response to antipsychotics in patients with schizophrenia (Zhang et al., 
2010). Dopamine is involved in pathways regulating feeding, motivation and 
sense of well-being (Blum et al., 2014). In animal models, DRD2 function is 
associated with hyperphagia, addictive behaviour and binge drinking (Blum 
et al., 2014). 
Adrenergic receptors are also the target of many atypical antipsychotics. 
Alpha 2A receptor has an inhibitory effect on fatty acid mobilization from 
adipose tissue. The SNP associated with weight gain in the meta-analysis of 
Zhang et al. is also associated with fat accumulation in the general population 
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(Garenc et al., 2002) and may affect plasma glucose, insulin and cortisol 
levels (Rosmond et al., 2002).   
GNB3 encodes a beta 3 subunit in heterotrimeric (i.e. constituting three 
subunits) G proteins, which are involved in intracellular signal pathways and 
transmitting signals from extracellular stimuli. The SNP identified to have an 
association with antipsychotic-induced weight gain is also associated with 
atherosclerosis, insulin resistance and obesity in the general population 
(Siffert, 2005).  
MC4R has also been linked with obesity in the general population (Zobel 
et al., 2009). The so-called melanocortin system in the hypothalamus is a 
neuronal circuit involved in maintaining energy homeostasis. Activation of 
the MC4R neurons causes decreased food intake and increases energy 
expenditure, while inhibition of these neurons results in decreased energy 
expenditure and weight increase (Kim et al., 2014). 
Of other genes associated with obesity or energy regulation in the general 
population, only BDNF and INSIG2 were modestly associated with 
antipsychotic-related weight gain in the meta-analysis. However, the results 
were not consistent, as BDNF was only linked with a categorical outcome of 
clinically significant weight gain (>7%), and the sample size of INSIG2 was 
small (Zhang et al., 2016). 
2.5.2 ANTIPSYCHOTICS’ EFFECTS ON GLUCOSE METABOLISM 
2.5.2.1 Blood glucose regulation and insulin resistance 
Blood glucose levels are regulated by insulin and glucagon with opposite 
effects. Insulin is released from pancreatic β-cells in response to increasing 
levels of blood glucose. It reduces blood glucose levels by increasing the 
storage of glucose in liver, skeletal muscle and fat. When the glucose level is 
low, insulin secretion decreases, and glucagon is released from pancreatic α-
cells, inducing glucose utilization and release from the liver and muscle, 
thereby increasing the level of glucose in the blood. Cortisol and the 
catecholamines adrenaline and noradrenaline also take part in the regulation 
of blood glucose levels by increasing the blood glucose concentration. 
Insulin resistance is a condition where the physiological effects of insulin 
are reduced, leading to increased levels of blood glucose and accelerated 
release of lipids from the adipocytes and glucose from the liver (Reilly and 
Saltiel, 2017). Obesity, especially abdominal obesity, has a strong association 
with insulin resistance (Despres and Lemieux, 2006), and insulin resistance 
is a major risk factor for developing type 2 diabetes (Kahn et al., 2006). 
Review of the literature 
36 
2.5.2.2 The effect of antipsychotics on glucose metabolism 
Apart from the effect on glucose metabolism that is mediated by weight gain, 
antipsychotics also alter glucose metabolism independently of weight. The 
effects on glucose metabolism (e.g. on insulin resistance) can occur 
substantially more rapidly than the effects on weight gain (Deng, 2013). 
Several receptor targets of antipsychotics disturb the physiological regulation 
of glucose levels by effects on insulin secretion, insulin sensitivity and 
appetite regulating mediators, such as leptin (Nasrallah, 2008).  
An example of the potential of antipsychotics to disturb glucose metabolism 
is diabetic ketoacidosis (DKA), which is a rare adverse effect of 
antipsychotics. In DKA, production of insulin is not adequate to control the 
blood glucose level and ketone bodies from free fatty acids cause acidosis 
(Guenette et al., 2013). DKA is a medical emergency with a considerable 
mortality rate. The risk of DKA is greatest with the antipsychotics that also 
cause the greatest weight gain, olanzapine and clozapine, but there are 
reports of aripiprazole-related DKA as well (Guenette et al., 2013; Vuk et al., 
2017).  
Olanzapine and clozapine are most consistently connected with elevated 
glucose levels and insulin resistance in schizophrenia. In the CATIE (Clinical 
Antipsychotic Trials of Intervention Effectiveness) study, a prospective 
randomized clinical study investigating the effectiveness of antipsychotics in 
patients with schizophrenia, olanzapine treatment was associated with 
increased HbA1c and glucose levels compared to risperidone, ziprasidone, 
perphenazine or quetiapine (Nasrallah, 2008). The risk of diabetes is 
greatest with SGA use, but FGA such as haloperidol and amisulpride are also 
associated with increased glucose levels (Deng, 2013; Nasrallah, 2008). 
Antipsychotics are associated with increased insulin resistance. Studies 
using homeostatic model assessment (HOMA, calculated as fasting glucose 
[mmol/l] x fasting insulin [mU/l]/22.5) as a measure of insulin resistance 
(Matthews et al., 1985) have shown that treatment with olanzapine, clozapine 
or risperidone is associated with increased insulin resistance (Deng, 2013). 
When comparing olanzapine and risperidone, the former seems to cause a 
larger decrease in insulin sensitivity measured by oral glucose tolerance test 
(Deng, 2013). HOMA measurement and hyperinsulinemic-euglycemic 
glucose clamp process (measurement of blood glucose levels under a 
constant insulin infusion (Muniyappa et al., 2007)) have also been used in 
animal studies, showing that treatment with olanzapine or clozapine causes 
insulin resistance and dysregulation of glucose metabolism (Deng, 2013). A 
study using a method of frequently sampled intravenous glucose tolerance 
test, where glucose and insulin levels are measured minute-by-minute after 
an intravenous glucose bolus, found that non-obese olanzapine- and 
clozapine-treated patients with schizophrenia had increased insulin 
resistance and decreased glucose effectiveness (i.e. measure of glucose 
clearance rate due to an increase in blood glucose independent of insulin) 
compared to patients treated with risperidone (Henderson et al., 2005). 
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Of antipsychotics’ receptor targets, 5-HT2C, H1 and muscarinic receptor 
affinities have been associated with increased risk of diabetes (Matsui-Sakata 
et al., 2005). 5-HT1A antagonism decreases insulin secretion and increases 
glucose levels by interfering with pancreatic beta-cell function. Moreover, 5-
HT2A receptor antagonism has been found to decrease glucose uptake to 
skeletal muscle and thus increase glucose levels. In animal studies, 5-HT2C-
deficient mice display insulin resistance, increased blood glucose and weight 
gain. The mechanism by which histamine H1 receptor antagonism is 
associated with increased glucose level may be leptin dependent. H1 blockade 
interferes with leptin-mediated anorexigenic signalling (Matsui-Sakata et al., 
2005; Nasrallah, 2008). Muscarinic acetylcholine M3 receptors are 
expressed in pancreatic beta-cells where they take part in the regulation of 
insulin secretion. Olanzapine and clozapine, which both have antagonistic 
effect on M3 receptors, impair acetylcholine-mediated insulin secretion in 
animal studies (Nasrallah, 2008). 
2.5.2.3 Are antipsychotic-induced metabolic changes evident without 
a psychotic disorder? 
A meta-analysis aiming to clarify the connection between insulin resistance 
and weight gain during antipsychotic treatment, independent of the effect of 
the psychiatric disease, pooled together studies done with healthy volunteers 
(Burghardt et al., 2018). Atypical antipsychotics were found to reduce insulin 
sensitivity (standardized mean difference [SMD] -0.437) and increase weight 
(SMD 0.591) in healthy volunteers. Insulin resistance was dependent on 
treatment length but not on weight gain. It is of note that the range of length 
of the studies included in the meta-analysis was from single-dose to 28 days. 
Most of the studies compared 10mg of olanzapine to placebo. Significant 
reduction in insulin sensitivity was observed in studies ranging 3-14 days, 
and weight gain was observed only in studies of 14-28 days.  
The meta-analysis by Burghardt et al. (2018) indicates that antipsychotics 
also induce insulin resistance and weight gain in individuals without a 
psychiatric disorder. Antipsychotic-induced insulin resistance seems to 
precede weight gain, which takes more time to develop. In addition to 
disturbing glucose metabolism, antipsychotics also have effects on lipids 
which will be reviewed in the next section. 
2.5.3 EFFECTS OF ANTIPSYCHOTICS ON LIPID METABOLISM 
The first studies addressing the effect of FGA on lipid levels showed that the 
use of FGA was associated with increased levels of triglycerides and total 
cholesterol (Meyer and Koro, 2004). Phenothiazine compounds, such as 
chlorpromazine, were noted to be more strongly associated with increased 
lipid levels than high-potency butyrophenones, such as haloperidol (Meyer 
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and Koro, 2004). Of SGA, olanzapine and clozapine use has been shown to 
increase triglyceride and both total and low-density lipoprotein (LDL) 
cholesterol, while risperidone use in comparison to the former has a lower 
propensity to increase lipid levels. Antipsychotics that have a lower risk for 
weight gain, e.g. ziprasidone and aripiprazole, are also associated with 
smaller effects on lipids (Gonçalves et al., 2015; Meyer and Koro, 2004).  
In animal models, treatment with antipsychotics induces the synthesis of 
phospholipids, triglycerides and free fatty acids in the liver, which are then 
either stored in the hepatocytes or released into the circulation in very low-
density lipoprotein particles (Gonçalves et al., 2015). Olanzapine has also 
been found to decrease lipolysis, which further contributes to the increase in 
fat tissue (Albaugh et al., 2012).  
Antipsychotics have been found to upregulate SREBP (sterol regulatory 
element-binding proteins) controlled genes (Fernø et al., 2005). SREBPs are 
transcription factors that bind to a specific DNA sequence called the sterol 
regulatory element and thereby increase the transcription of enzymes taking 
part in cholesterol and fatty acid biosynthesis (Brown and Goldstein, 1997). 
However, antipsychotics’ effects on the lipid biosynthesis pathways are 
complex and involve feedback mechanisms that result in rapid changes in the 
enzyme activities. This is reflected in a study investigating the in vitro effects 
of different SGA on lipid biosynthesis (Canfran-Duque et al., 2013). All the 
SGA included (clozapine, risperidone and ziprasidone) inhibited cholesterol 
synthesis by altering the activity of various enzymes involved in the pathway 
(Canfran-Duque et al., 2013). After the removal of the antipsychotic from the 
culture medium, a rebound effect was detected with an increase in 
cholesterol, phospholipid and triglyceride synthesis (Canfran-Duque et al., 
2013). Taken together, antipsychotics modify lipid metabolism resulting in 
increased levels of total and LDL cholesterol and triglycerides. Antipsychotics 
have complex effects on lipid biosynthesis but the net effect seems to be an 
increase in the synthesis rate. The effects of antipsychotics are at least partly 
independent of weight gain, although antipsychotics with the greatest weight 
gain potential are also most strongly associated with dyslipidemia. 
2.6 COURSE AND PROGNOSIS OF FIRST-EPISODE 
PSYCHOSIS 
Outcome in psychotic disorders varies widely (Revier et al., 2015). Key 
concepts in defining the course of a disease are remission, meaning a 
significant reduction in symptoms to a level that is not detrimental to 
functioning or causing distress, and recovery, absence of significant 
symptoms and regaining the premorbid level of functioning for a prolonged 
period of time.  
Remission and recovery in psychosis, and factors associated with varying 
outcomes, have been less of a focus for research than the factors affecting the 
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onset of psychoses. This is perhaps because dementia praecox, the 
predecessor of schizophrenia as a disease entity, was originally defined by 
Kraepelin as a chronic, unremitting illness, and recovery was thought to be 
rare and anomalous. The poor outcome itself was one of the defining features 
of the disease. Despite observations that a significant proportion of patients 
remitted at times, and that there were cases of partial recovery, the 
intractable and declining nature of schizophrenia was still considered a 
hallmark of schizophrenia during the era of Kraepelin. With the development 
of antipsychotic pharmacotherapy from the middle of the 20th century 
onwards, remission and recovery rates became of more interest, as new 
possibilities in treating psychotic disorders gave hope for a better prognosis 
in psychotic disorders (Frese et al., 2009). 
In the past decades, definitions of remission and recovery in psychosis 
varied, as there was no official agreement on these concepts. The Remission 
in Schizophrenia Working Group (RSWG) was established to formulate a 
consensus on remission criteria in schizophrenia, which it published in 2005 
(Andreasen et al., 2005). RSWG defined remission in schizophrenia as a 
period of at least 6 months with only mild or no symptoms (a corresponding 
BPRS score of ≤3 in certain items measuring psychotic symptoms and 
disorganization, and SANS score ≤2 in each item) such that the symptoms do 
not interfere with behaviour and functioning. The working group stated that 
remission is a necessary but not sufficient step towards recovery, which it 
defined as a process of longer duration, but for which it provided no 
operational criteria. Recovery has been defined multidimensionally, 
including symptom-level and functional (social, occupational and 
educational function) improvement (Emsley et al., 2011; Jääskeläinen et al., 
2013; Warner, 2009).  
A meta-analysis (Lally et al., 2017) found that 57-59% of patients with 
FEP met the criteria for remission during an average follow-up period of 5.5 
years (using the RSWG remission criteria with and without the 6-month 
duration requirement). The rate of remission was higher in more recent 
studies, possibly reflecting the improved care of FEP in specialized tertiary 
clinics. The other potential moderators did not have a significant effect on 
the rate of remission, including duration of untreated psychosis, adherence 
to antipsychotic medication, ethnicity, employment status or being single.  
The meta-analysis by Lally et al. also analysed recovery rates using 
criteria for recovery as in Jääskeläinen et al. (2013) (i.e. domains of clinical 
and social recovery with only mild symptoms, at least one of them persisting 
for minimum two years). The pooled recovery rate was 38% during a follow-
up of 7.2 years. The rate of recovery was lower in more recent studies 
(published between 1997-2016) (32%) compared to older studies (1976-1996) 
(45%). The rate of recovery was not reduced with a longer duration of follow-
up (2-6 years of follow-up compared to over 6 years), implying that the 
course of psychotic disorders is not necessarily deteriorating and the early 
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recovery rate is maintained over longer periods of follow-up (Lally et al., 
2017). 
Using a stricter definition of recovery than the RSWG, a meta-analysis by 
Jääskeläinen et al. (2013), comprising 50 studies on multi-episode and first-
episode schizophrenia, found that only 13.5% of people with schizophrenia 
recovered with a median annual recovery rate of 1.4%. This proportion was 
smaller than previous estimates of approximately 40% of patients with good 
outcome in schizophrenia or FEP (Hegarty et al., 1994; Menezes et al., 2006).  
To summarize, the recent meta-analysis by Lally et al. (2017) suggests 
that the prognosis in FEP is considerably better in terms of recovery rates 
than in schizophrenia. Unlike remission rates, the recovery rates in FEP seem 
not to have improved during recent decades, a finding that warrants further 
research. FEP does not necessarily show a deteriorating course, as the 
recovery rate does not seem to decline in time. Nevertheless, the prognosis in 
schizophrenia is relatively poor, with only a minority of individuals 
experiencing an extended period of time with minimal symptoms and good 
functioning.  
2.7 METABOLIC CHANGES IN FIRST-EPISODE 
PSYCHOSIS 
2.7.1 ANTHROPOMETRIC AND METABOLIC PARAMETERS IN 
DRUG-NAÏVE PATIENTS 
Whether people with first-episode psychosis have an inherent vulnerability 
for weight gain and metabolic disturbances, independent of the effects of 
antipsychotic medication, is a topic of great interest and clinical importance. 
In historical publications, before the era of the first antipsychotic agent 
chlorpromazine, people with dementia praecox were described to have 
glucose levels similar to those of patients with diabetes (Kohen, 2004). These 
reports, which were case studies or small inpatient cohorts, found 
hyperglycaemia and decreased glucose tolerance in patients with dementia 
praecox. Another observation that prompted the early research on glucose 
metabolism in psychosis was an observation made when treating patients 
with psychotic symptoms with insulin-induced hypoglycaemic coma therapy, 
which was a widely used treatment method from the first half of the 20th 
century until the late 1950s. With poor results and causing tremendous 
suffering to the patients, repeated insulin injections were given in order to 
produce a hypoglycaemic state with convulsions and coma. Some clinicians 
administering the insulin noted that patients with schizophrenia had a 
decreased response to insulin compared to people without the illness. This 
led researchers to speculate whether the carbohydrate metabolism of the 




One potential factor resulting in harmful metabolic changes in people 
with FEP is a reduction of physical activity and other changes in lifestyle 
associated with the declining ability to function. The prodromal period, 
which often precedes the onset of psychosis, is characterized by symptoms of 
depression and anxiety, social withdrawal and a decline in the level of 
functioning. This, with the onset of positive symptoms, may lead to reduction 
in physical activity and to a lifestyle that is detrimental to physical health. 
Both sedentary lifestyle (Stubbs et al., 2016) and poor diet (Dipasquale et al., 
2013) are common among people with schizophrenia.  
A systematic review on metabolic changes in people with FEP, comprising 
25 studies, found that among 7 studies reporting case-control differences 
before antipsychotic treatment, three studies found higher waist-to-hip ratio 
in patients, and one study that matched for BMI reported significantly more 
intra-abdominal fat in patients compared to controls (Foley and Morley, 
2011). Patients and controls did not have differences in BMI, total body fat, 
weight or waist circumference before antipsychotic treatment. Also, no 
systematic differences were found in laboratory parameters such as lipid or 
glucose metabolism, nor in adiponectin or leptin levels (Foley and Morley, 
2011).  
Recent meta-analyses have examined changes in glucose and lipid 
parameters in patients with first-episode psychosis with minimal or no 
antipsychotic exposure. Increased fasting glucose, impaired glucose tolerance 
and insulin resistance were detected in FEP patients (Pillinger et al., 2017a). 
In another meta-analysis, FEP patients had reduced total and LDL 
cholesterol and increased triglyceride levels compared to controls, while no 
differences were detected in high-density lipoprotein (HDL) cholesterol 
levels (Pillinger et al., 2017b). However, in sensitivity analysis matched for 
ethnicity, the differences in total cholesterol and triglycerides were no longer 
significant. Furthermore, in a sensitivity analysis matched for BMI, the 
difference in triglycerides was not significant. In a meta-analysis 
investigating lipid levels in antipsychotic-naïve patients with first-episode 
non-affective psychosis, patients had lower total, LDL and HDL cholesterol 
levels, and higher triglyceride levels compared to controls (Misiak et al., 
2017). 
In the European First-Episode Schizophrenia Trial (EUFEST), among 
drug-naïve patients with first-episode schizophrenia (n=157) the prevalence 
of MetS was 5.7%, similar to the general population of the same age 
(Fleischhacker et al., 2013). 
A meta-analysis, assessing metabolic abnormalities in unmedicated 
patients with FEP, found that the prevalence of metabolic syndrome and 
metabolic risk factors were low in relation to medicated multi-episode 
psychosis patients (Mitchell et al., 2013a). Of unmedicated patients with 
FEP, 9.8% had metabolic syndrome using any of the standardized criteria, 
and the prevalence of each of the individual metabolic risks (increased waist 
Review of the literature 
42 
circumference, hypertension, hyperlipidemia) was above 20%. (Mitchell et 
al., 2013a).  
In conclusion, metabolic changes in FEP seem to be already partly present 
before medication. Dysregulated glucose metabolism and high triglycerides 
are among the most consistently reported findings. This is suggested to be 
due to intrinsic factors like dysregulated HPA axis, or external factors like 
stress. Unfortunately, these changes seem to further escalate during 
psychotropic medication, as described in the next paragraphs.   
2.7.2 MEDICATION FURTHER INCREASES METABOLIC CHANGES 
IN FIRST-EPISODE PSYCHOSIS PATIENTS 
With increasing duration of illness and antipsychotic medication, several 
studies show significant changes in anthropometric and metabolic 
parameters in FEP. In a systematic review by Foley and Morley (2011), 
weight gain and increase in waist circumference were already evident after 
one month of treatment with antipsychotics. Olanzapine was associated with 
more weight gain by 8 weeks than risperidone or haloperidol. By 8 weeks, 
increases in insulin resistance, glucose levels, as well as cholesterol and 
triglyceride levels were observed. In studies with a follow-up of 3-4 months, 
weight gain was consistently reported but changes in metabolic parameters 
were inconclusive, with some studies reporting increases in glucose and lipid 
levels while others did not find similar differences (Foley and Morley, 2011). 
In studies with a follow-up of one year, olanzapine was again associated with 
the greatest weight gain (11-17kg). Significant increases in insulin, insulin 
resistance, total and LDL cholesterol, triglyceride, leptin and ghrelin levels 
were reported in studies following patients for one year (Foley and Morley, 
2011). 
A study reporting the baseline results from the US-based RAISE 
(Recovery After an Initial Schizophrenia Episode) study found that of the 394 
first-episode schizophrenia patients included in the study, 48% were 
overweight, 51% smoked, 57% had lipid abnormalities, 10% had hypertension 
and 13% had metabolic syndrome (Correll et al., 2014). In addition, 15% of 
patients had HbA1c-defined prediabetes. The patients had a mean lifetime 
antipsychotic treatment of 47 days. Antipsychotic treatment duration was 
associated with higher non-HDL cholesterol, triglycerides, lower HDL 
cholesterol and systolic blood pressure. Duration of illness was associated 
with anthropometric measures (weight, fat mass and percentage, waist 
circumference). Although the prevalence of overweight and obesity in this 
sample did not differ from findings in the general population in the United 
States, MetS and dyslipidemia were more common than in the general 
population of similar age. Furthermore, smoking was more common among 
patients than the general population (respective percentages among men 
55.9% vs. 36.7% and women 36.8% vs. 24.9%). 
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In the EUFEST study, 52-week changes in body weight, waist 
circumference, hyperglycaemia, insulin resistance and lipids were compared 
across groups of first-episode schizophrenia patients treated with five 
different antipsychotics (amisulpride, haloperidol, olanzapine, quetiapine 
and ziprasidone). Increase in weight ranged from 0.18kg/month 
(ziprasidone) to 0.98kg/month (0lanzapine). In the amisulpride and 
olanzapine groups, a statistically significant rise in insulin resistance was 
observed. Proportions of patients with a shift from normal triglyceride levels 
to hypertriglyceridemia and a reduction in HDL cholesterol levels were 
greatest in the amisulpride (29.2% and 22.5% respectively) and olanzapine 
(21.4% and 24.1%) groups over the 52-week study period. All antipsychotics 
were associated with increase in glucose levels with no statistically significant 
differences between treatment groups (Fleischhacker et al., 2013). 
Providing further evidence of the longitudinal increase in cardiometabolic 
risk in FEP with antipsychotic treatment, a study examined differences in the 
incidence and prevalence of MetS in FEP patients treated with FGA 
compared to patients treated with SGA (De Hert et al., 2008). During a 3-
year follow-up, an almost 5-fold increase in the prevalence of MetS was 
detected in the SGA group over the study period (baseline prevalence 5.6% 
vs. 3-year prevalence 30.6%). This was a markedly higher increase than the 
prevalence in the FGA group (baseline prevalence 5.7% vs. 3-year prevalence 
13.1%). The higher increase in the prevalence in the SGA group was mostly 
due to the harmful metabolic effects of clozapine and olanzapine. Patients 
treated with clozapine at the 3-year measurement had a MetS prevalence of 
58.3%, and those treated with olanzapine 47.1%. In contrast, the prevalence 
of MetS was lowest in those treated with aripiprazole (10.0%). Another study 
on medication-naïve FEP patients found a 12.1kg mean weight gain among 
170 patients during a 3-year follow-up (Perez-Iglesias et al., 2014). The 
weight gain was rapid during the first year of antipsychotic treatment, 
accounting for 85% of the total weight gain. Total cholesterol, LDL 
cholesterol and triglycerides increased significantly from baseline to the one-
year assessment, while the change in HDL cholesterol was slower, reaching a 
statistical significance at the two-year assessment. Changes in glucose, 
insulin and HOMA levels were not statistically significant, although a trend 
for increases in HOMA and insulin were observed (Perez-Iglesias et al., 
2014). 
In conclusion, studies consistently show how weight gain and an 
unfavourable lipid profile develop rapidly during the first months of 
psychopharmacological treatment, and this development continues even 
longer. While these metabolic changes already increase cardiovascular risk 
considerably, the changes are accompanied by a systemic low-grade 
inflammation adding to the risk. 
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2.8 LOW-GRADE INFLAMMATION IN PSYCHOTIC 
DISORDERS 
2.8.1 MECHANISMS OF LOW-GRADE INFLAMMATION 
Inflammation is an organism’s response to factors that are perceived as 
threatening the survival of the organism (e.g. infection or physical injury). 
Inflammation has adaptive functions: initiating the process of removal of the 
threat (e.g. bacteria or viruses causing an infection) and the healing of 
damaged tissue. By recruiting a variety of defense mechanisms, the organism 
aims to prevent any further damage by the infectious or other physically 
insulting agent. The immune system is divided into the innate and adaptive 
immune systems (Chaplin, 2010). The innate immune system consists of 
physical barriers (e.g. epithelial layers of gastrointestinal and respiratory 
tracts, mucus and saliva), immune cells, complement system and cytokines. 
Immune cells of the innate system, neutrophils and monocytes, and the cells 
deriving from monocytes (dendritic cells, macrophages, mast cells and 
eosinophils) take part in clearing out the infectious agent by detecting foreign 
substances and attempting to neutralize them. By antigen presentation, 
dendritic cells also activate the T and B lymphocytes of the adaptive immune 
system. The B lymphocytes secrete pathogen-specific antibodies and thus 
activate a range of immune mechanisms against the pathogen. T lymphocytes 
have differing functions, including elimination of the pathogen and 
regulation of the immune response. Cytokines and chemokines, secreted by 
the immune cells and various other cell types, orchestrate the immune 
activation by increasing or decreasing the inflammatory activity (Chaplin, 
2010).  
In addition to providing vital protection for the survival of the host 
organism, inflammation can also be maladaptive, causing effects that are 
harmful for the survival and well-being of the host. In the case of infection or 
physical damage, inflammation is a transient process, usually leading to 
successful removal of the insulting agent and healing of the tissues. In 
chronic inflammation, such that is present in obesity, the immune system is 
not able to remove the inflammation-inducing factors. This leads to a 
persisting pro-inflammatory activation. The low-grade, chronic inflammation 
is associated with obesity and the many complications of obesity, such as 
insulin resistance, T2D and cardiovascular disease (Gregor and Hotamisligil, 
2011). 
In obesity, excessive fat accumulation causes a pathological state in the 
adipocytes which are forced to adapt to an environment with abundant 
nutrients and increased levels of insulin (Reilly and Saltiel, 2017). Increased 
number of adipocyte cell death, mechanical stress of cell and tissue 
expansion and hypoxia all contribute to an inflammatory reaction, which in 
itself is adaptive, aiming to increase the chance of survival of the adipocytes, 
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e.g. by increasing vascularization of the adipose tissue. In response to 
increased pro-inflammatory cytokine production by the adipocytes, pro-
inflammatory macrophages, mast cells and T cells invade the adipose tissue 
(Gregor and Hotamisligil, 2011). In addition, obesity is associated with 
increased permeability of the intestinal mucosa, which may lead to leakage of 
gut-derived antigens, such as lipopolysaccharide (LPS), the major 
component of the outer membrane of gram-negative bacteria, to the blood. 
LPS is detected by the adipocytes in the mesenteric adipose tissue 
surrounding the gut. Ingested lipids may also act as antigens, provoking 
further pro-inflammatory activation (Reilly and Saltiel, 2017). 
2.8.2 C-REACTIVE PROTEIN AS A MARKER FOR LOW-GRADE 
INFLAMMATION 
CRP is the most widely available inflammatory marker in clinical medicine. 
CRP is an acute-phase protein produced mainly by hepatic cells in response 
to inflammatory cytokines, primarily interleukin-6 (Castell et al., 1990). In 
addition to liver cells, adipocytes may also produce CRP in obese individuals 
(Anty et al., 2006). CRP takes part in the innate immune process of host 
defense by binding to the surface of microbes or to components released 
from damaged cells, which leads to activation of the complement cascade 
(Pepys and Hirschfield, 2003). 
Low-grade inflammation can be measured with hs-CRP with better 
sensitivity than regular assays. CRP correlates with BMI and waist 
circumference in the general population (Choi et al., 2013). Hs-CRP is an 
independent risk factor for cardiovascular disease of the same magnitude as 
LDL cholesterol and independent of it (Ridker, 2016). Values of hs-CRP 
below 1mg/l mark low cardiovascular risk, values between 1-3mg/l 
intermediate risk and above 3mg/l increased risk (Ridker, 2016). 
Furthermore, hs-CRP is a risk factor for vascular and non-vascular mortality 
in the general population (Emerging Risk Factors Collaboration et al., 2010). 
In the general population, significant changes in hs-CRP levels are not 
common; in fact, just as cholesterol and blood pressure levels, hs-CRP has 
been observed to stay relatively unchanged in individuals over a number of 
years (Emerging Risk Factors Collaboration et al., 2010). 
2.8.3 EVIDENCE OF LOW-GRADE INFLAMMATION IN PSYCHOTIC 
DISORDERS 
Low-grade inflammation has been observed in many psychiatric disorders, 
including major depression, bipolar disorder, schizophrenia and post-
traumatic stress disorder (Pinto et al., 2017). These disorders do not have 
specific inflammatory biomarker profile as many of the same biomarkers are 
shared by the disorders (Pinto et al., 2017). This may reflect the fact that the 
psychiatric disorders also share similarities in their molecular background 
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(Gandal et al., 2018), and that the disorders are associated with lifestyle 
factors, stress and metabolic changes which can all induce pro-inflammatory 
activation (Black, 2003). 
Four meta-analyses have been published on the association between CRP 
levels and schizophrenia or related psychoses. A meta-analysis by Miller et al. 
(2011) included eight individual cross-sectional studies measuring CRP in 
people with schizophrenia or related psychoses (schizophreniform disorder, 
brief psychotic disorder, psychotic disorder not otherwise specified, 
delusional disorder and schizoaffective disorder) and in healthy controls. The 
studies consisted of altogether 767 patients and 745 controls. According to 
the meta-analysis, people with schizophrenia or related psychoses had 
increased levels of CRP by a small-to-medium effect size of 0.45 (95% CI 
0.34-0.55, p<0.001) (Hedge’s g; where 0.2 is considered to indicate small 
effect, 0.5 a moderate effect and 0.8 a large effect (Higgins and Green, 
2011)). However, after excluding one (Fawzi et al., 2011) of the eight studies 
in a sensitivity analysis, the effect size dropped to 0.10 and was no longer 
statistically significant (p=0.10). In their meta-analysis, Miller et al. also 
looked into the prevalence of abnormal CRP (defined as CRP value >5mg/l) 
in five studies consisting of altogether 575 subjects with schizophrenia or 
related psychoses, and found that 28.0% of the subjects had an abnormal 
level of CRP. A limitation of the meta-analysis was, as discussed by the 
authors, that many of the included studies did not control for factors known 
to affect CRP levels, such as BMI, smoking or antipsychotic use. 
The largest meta-analysis on CRP levels and psychotic disorders 
published to date was conducted by Fernandes et al. (2016), including 26 
cross-sectional or longitudinal studies and 85000 participants diagnosed 
with schizophrenia, schizophreniform or schizoaffective disorder. The 
authors did a between-group meta-analysis, consisting of 19 studies, to 
investigate differences in CRP levels between patients with psychotic 
disorders and healthy controls. They also conducted two within-group meta-
analyses consisting of six and three studies to clarify the effects of 
antipsychotic initiation and antipsychotic change on CRP levels. The 
between-group meta-analysis showed that people with psychotic disorders 
had higher CRP levels than controls with an effect size of 0.66 (95% CI 0.43-
0.88, p<0.0001). In meta-regression analyses, CRP levels were associated 
with positive symptom severity, but no association between CRP levels and 
negative symptoms were detected. There was a positive association with BMI 
and CRP levels (slope=0.21, 95% CI 0.04-0.29, p=0.004). However, the 
authors detected no association between CRP and waist circumference 
(slope=0.01, 95% CI 0.07-0.09, p=0.867). The within-group meta-analyses 
showed that there were no statistically significant differences in CRP levels 
before and after the initiation of antipsychotic treatment (range of follow-up 
4-52 weeks) or after a switch of antipsychotic, regardless of whether the 
switch was within or across the classes of FGA and SGA. 
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Inoshita et al. (2016) included 14 case-control studies (1664 patients with 
schizophrenia, 3070 controls) in their meta-analysis on CRP levels in 
schizophrenia. They reported significantly higher CRP levels in patients with 
schizophrenia (SMD 0.62, 95% CI 0.24-0.99, p=0.0014). No analysis of the 
possible confounding effect of BMI or waist circumference in CRP levels was 
included. 
Wang et al. (2017) based their meta-analysis on 18 case-control studies on 
schizophrenia and related psychoses. They found moderately increased CRP 
levels in people with psychoses (SMD 0.53, 95% CI 0.30-0.76). Similar to the 
meta-analysis by Fernandes et al., Wang et al. reported that increase in CRP 
was not explained by higher BMI in people with psychosis, and with 
increasing age the difference in CRP levels between people with 
schizophrenia and controls decreased. 
It is noteworthy that the meta-analyses conducted on CRP levels in 
schizophrenia have high heterogeneity among individual studies. 
Heterogeneity can be measured by I2 which varies between 0% and 100%, 
and reflects inconsistency in the findings of individual studies (Higgins et al., 
2003). The meta-analyses on CRP and schizophrenia all have an I2 above 
90%, indicating that there is marked heterogeneity among the studies 
included. This might arise because of differences in the selection of 
participants for the studies (e.g. stage of illness, duration of antipsychotic 
use), differences in exclusion criteria (eg. infections, chronic physical 
illnesses), and differences in the method of selection of control subjects. The 
reasons underlying high heterogeneity were further explored in the meta-
analysis by Fernandes et al. (2016), where heterogeneity was higher in 
clinical studies than in population-based studies, but was not explained by 
any other single variable. 
2.8.3.1 Is high CRP causally correlated with risk of psychosis? 
Mendelian randomization (MR) is a method of analysing the genetic 
variation of a risk factor and its association with an outcome. It can be 
utilized to clarify possible causal connections between a putative risk factor 
and the associated outcome when there is a known genetic variation affecting 
the risk factor, and when this genetic variation does not directly influence the 
outcome. MR studies conducted on CRP and risk of schizophrenia use 
information of certain SNPs that affect levels of CRP in large samples, and 
aim to test whether this genetically determined level of CRP is connected to 
the risk of schizophrenia. MR eliminates the common problems of 
observational studies, reverse causation (meaning that the observed outcome 
influences the exposure) and confounding factors (unaccounted factors 
affecting both the exposure and outcome variables, thus leading to a false 
association) (Hartwig et al., 2016). 
Several MR studies have been conducted to clarify whether genetically 
predicted CRP levels are causally connected with the risk of schizophrenia 
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(Hartwig et al., 2017; Inoshita et al., 2016; Prins et al., 2016; Wium-Andersen 
et al., 2014). The results have been inconsistent, as some studies have found 
the genetic variations connected with elevated CRP levels to be associated 
with increased risk of schizophrenia (Inoshita et al., 2016; Wium-Andersen 
and Wium-Andersen, 2016), while other studies have reported an inverse 
finding (Hartwig et al., 2017; Prins et al., 2016). For example, a MR study by 
Hartwig et al. (2017) found that genetic predisposition for higher CRP levels 
had a protective effect: with each 2-fold increase in the predicted CRP level, 
risk of schizophrenia decreased by an odds ratio of 0.90 (random effects 95% 
CI 0.84–0.97, p=0.005). The mechanism behind the association of lower 
levels of CRP and schizophrenia risk is unknown. The authors suggested that 
higher levels of CRP might provide protection from early life infections and 
thus decrease the risk of schizophrenia (Hartwig et al., 2017). Interestingly, 
this hypothesis is in accordance with another study that reported higher 
levels of acute-phase proteins in newborns associating with lower risk of later 
non-affective psychosis (Gardner et al., 2013). 
In summary, studies attempting to clarify whether there is a causal 
connection between CRP levels and schizophrenia have come up with 
discordant results. Even if no genetic mechanism behind CRP levels and risk 
of schizophrenia were found, this does not necessarily exclude a role for 
inflammatory activity in the aetiology of psychotic disorders. Nevertheless, 
there are a multitude of confounding factors when measuring inflammation 
in psychotic disorders, including physical disease, obesity, stress and 
medication (Manu et al., 2014). Revealing distinct inflammatory processes 
with aetiological significance would require more studies that control for 
these factors and follow individuals throughout the disease process from at-
risk states to psychosis. 
 
2.9 PHYSICAL COMORBIDITY AND MORTALITY IN 
PSYCHOTIC DISORDERS 
2.9.1 CARDIOVASCULAR RISK FACTORS AND 
CARDIOVASCULAR DISEASE IN PEOPLE WITH PSYCHOTIC 
DISORDERS 
People with chronic psychotic disorders have a high prevalence of co-
occurring physical disease, i.e. physical comorbidity (Crump et al., 2013b; 
Laursen et al., 2011). Various factors predispose people with psychotic 
disorders to physical comorbidity, including low level of physical activity, 
smoking, low quality diet and antipsychotic medication. Table 3 shows major 
physical comorbidities and their estimated prevalence or incidence in 
psychotic disorders or other SMI.  
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Obesity is defined as BMI 30kg/m2. The global prevalence of obesity has 
been increasing during recent decades, tripling since 1975. Globally in 2016, 
15% of women and 11% of men were obese (WHO World Health 
Organization, 2018). In Finland, one fourth of the adult population is obese 
(Koponen et al., 2018). Obesity increases the risk of cardiovascular disease, 
diabetes, cancer and musculoskeletal disease, such as arthrosis (Bray, 2004). 
In the general population, obesity is associated with increased all-cause, 
vascular, diabetic and cancer mortality (Prospective Studies Collaboration, 
2009).  As reviewed in section 2.5.1, antipsychotic medication is a major 
driver for obesity in people with psychotic disorders. Fat accumulation that is 
associated with antipsychotic use concentrates especially in the abdomen, 
leading to abdominal obesity, subsequent metabolic dysregulation (i.e. 
inflammation, hypertriglyceridemia and insulin resistance) and increased 
risk of physical comorbidity (Gonçalves et al., 2015).  
MetS consists of abdominal obesity, hyperglycaemia, increased 
triglycerides, low HDL and hypertension (Alberti et al., 2009). MetS is 
associated with a 2-fold increased risk of cardiovascular disease over 5-10 
years and with a 5-fold risk of type 2 diabetes in comparison to people 
without the syndrome (Alberti et al., 2009). There have been various 
modifications to the criteria for MetS. In 2001, the National Cholesterol 
Education Program of the United States published the ATPIII (Adult 
Treatment Panel III) criteria for MetS (Expert Panel on Detection Evaluation 
and Treatment of High Blood Cholesterol in Adults, 2001). The new criteria 
abandoned the insulin resistance/glucose intolerance criterion, which was 
included in previous definitions of MetS, with the rationale that waist 
circumference is correlated with insulin resistance, and in the clinical setting 
fasting glucose is more easily available than measures of insulin resistance. 
The International Diabetes Federation (IDF) introduced their criteria for 
MetS in 2005, modifying the ATPIII criteria with ethnicity-specific cut points 
for waist circumference and lower cut point (5.6mmol/l) for elevated fasting 
glucose (International Diabetes Federation, 2006). The IDF criteria also 
emphasized the significance of abdominal obesity in MetS by making 
increased waist circumference a prerequisite for the diagnosis. 
The American Heart Association and the National Heart, Lung, and Blood 
Institute (AHA/NHLBI) made minor changes to the ATPIII criteria in 2005: 
they lowered the fasting glucose cut point from 6.1mmol/l to 5.6mmol/l to 
correspond with the American Diabetes Association’s definition for impaired 
fasting glucose (Grundy et al., 2005). In the manner of IDF, AHA/NHLBI set 
ethnicity-specific cut points for waist circumference, specifying that some 
people with marginally increased waist circumference (especially people with 
Asian ethnicity, for whom lower cut points for waist circumference should be 
used) will have a genetic predisposition for insulin resistance and should 
therefore be treated accordingly, even if the required limit of ≥102cm in men 
or ≥88cm in women is not met (Grundy et al., 2005). Table 4 shows the 
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Table 4. ATPIII criteria modified by AHA/NHLBI and IDF criteria for 
metabolic syndrome 
 AHA/NHLBI modification of 
ATPIII (2005) 
IDF (2005) 
Required Any 3 of the 5 criteria Elevated waist circumference 
+ 2 of the 4 criteria 
Waist 
circumference 
≥102cm in men, ≥88cm in 
women 
Ethnicity specific.* European 
ancestry: ≥94cm in men, 
≥80cm in women 
Elevated 
triglycerides 
≥1.7mmol/l or specific 
treatment 
≥1.7mmol/l or specific 
treatment 
Reduced HDL <1.03mmol/l in men, 
<1.3mmol/l in women, or 
specific treatment 
<1.03mmol/l in men, 




≥130mmHg systolic or 
≥85mmHg diastolic, or 
antihypertensive treatment 
≥130mmHg systolic or 




≥5.6mmol/l or treatment for 
elevated glucose 
≥5.6mmol/l or treatment for 
elevated glucose 
*If BMI >30kg/m2, elevated waist circumference can be assumed. 
AHA/NHLBI, American Heart Association / National Heart, Lung, and Blood 
Institute; ATPIII, Adult Treatment Panel III; IDF, International Diabetes Federation; 
HDL, high-density lipoprotein cholesterol; BMI, body mass index 
 
Diabetes mellitus is traditionally divided into type 1 (with deficient insulin 
production) and type 2 (characterized by insulin resistance). However, this 
division is not definite, as many individual patients with diabetes fall 
somewhere between the two categories. The global prevalence of diabetes has 
almost doubled from 4.7% in 1980 to 8.5% in 2014 (WHO World Health 
Organization, 2017). In Finland, it is estimated that approximately 500 000 
people have diabetes, and the number of people having a right for 
reimbursement for medication used to treat diabetes has doubled during the 
previous 12 years. Most of this increase is due to the increase in the 
prevalence of T2D (Working group set up by the Finnish Medical Society 
Duodecim the Finnish Society of Internal Medicine and the Medical Advisory 
Board of the Finnish Diabetes Society, 2018). In addition to genetic risk 
factors (Almgren et al., 2011), obesity and lack of physical activity are the 
main risk factors for T2D (WHO World Health Organization, 2017). T2D is 
diagnosed when in two separate measurements fasting glucose is 
≥7.0mmol/l or after 2-hour oral glucose tolerance test >11mmol/l, or HbA1c 
is ≥48mmol/mol (≥6.5%) in a single measurement. In addition, a single 
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measurement of blood glucose >11mmol/l is sufficient for the diagnosis if 
classical symptoms of diabetes (thirst, weight loss, excessive urination) are 
present (Working group set up by the Finnish Medical Society Duodecim the 
Finnish Society of Internal Medicine and the Medical Advisory Board of the 
Finnish Diabetes Society, 2018).  
Dyslipidemia is a major risk factor for atherosclerosis and cardiovascular 
disease (including coronary heart disease, stroke and peripheral arterial 
disease). Dyslipidemia is diagnosed when total plasma cholesterol exceeds 
3.0mmol/l, triglycerides >1.7mmol/l, or HDL <1.0mmol/l in men or 
<1.2mmol/l in women. In 2008, the global prevalence of elevated total 
cholesterol was 39% (WHO World Health Organization, 2011). In Finland, 
nearly 60% of the population over 30 years of age have increased total 
cholesterol and about 50% have increased LDL cholesterol (Koponen et al., 
2018). In addition to antipsychotics, a diet with high saturated fat and low 
fibre content, low level of physical activity, smoking, high alcohol use and 
genetic factors may increase lipid levels and the risk of atherosclerotic 
vascular disease. Hypertriglyceridemia and low HDL are associated with 
insulin resistance and T2D (Li et al., 2014), although the causal connection 
between hypertriglyceridemia and low HDL with T2D is unclear (De Silva et 
al., 2011; Haase et al., 2015; Qi et al., 2012). 
Risk of cancer is generally increased by high alcohol consumption, 
smoking, obesity, low level of exercise and low intake of fruit and vegetables. 
Thus, it might be reasonable to expect the risk of cancer to be higher in 
people with psychotic disorders than in the general population. However, the 
findings on cancer have been inconsistent, and generally pointing in the 
direction that cancer incidence is not increased in people with psychosis 
(Kisely et al., 2013). The shorter lifespan of people with psychotic disorders 
due to other causes, and lower participation of cancer screening, may result 
in lower incidence rates of cancer in this population (De Hert et al., 2011b). 
2.9.2 INCREASED MORTALITY IN PSYCHOTIC DISORDERS 
In epidemiological studies on mortality, mortality rates are often reported. 
Mortality rate is defined as number of deaths per year per 1000 individuals. 
Mortality rates in different populations can be compared by mortality rate 
ratio (MRR) or standardized mortality rate (SMR). MRR is defined as the 
mortality rate in a population of interest divided by the mortality rate in a 
comparison group. SMR is calculated by dividing the mortality rate in a 
specific population by the mortality rate in the general population. Another 
way to express differences in mortality is to calculate differences in years 
people in different populations live. For instance, the average age of death in 
people with schizophrenia is compared to the average age of death in the 
general population, and the difference is reported. Causes of mortality are 
divided into natural causes (i.e. disease) and unnatural causes (i.e. accident, 
suicide, homicide, poisonings or overdose). 
People with schizophrenia die 15-20 years earlier than the general 
population (Laursen et al., 2014). Even higher differences have been 
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reported: in a US study, the years of life lost per deceased with schizophrenia 
was 28.5 years (Olfson et al., 2015). The excess mortality is mainly due to 
medical comorbidity in particular cardiovascular disease, diabetes, cancer 
and respiratory disease (Crump et al., 2013b; Olfson et al., 2015; Suvisaari et 
al., 2013; Termorshuizen et al., 2013). In people with psychotic disorders, the 
mortality due to medical conditions is disproportionally high compared to 
morbidity, which may be partly explained by under-diagnosis or poor quality 
of treatment of physical comorbidities (Crump et al., 2013b). A systematic 
review on mortality in schizophrenia gathered 37 studies from 25 nations, 
and reported an SMR of 2.58 (10% and 90% quantiles 1.18-5.76) (Saha et al., 
2007). In a Finnish study, the all-cause SMR of people with SMI compared to 
the total population was 3.48 in men and 3.75 in women between 2008-2010 
(Lumme et al., 2016).  
Various studies indicate that although in the general population mortality 
due to cardiovascular disease and cancer has been steadily decreasing, 
similar improvement is not observed in people with SMI (Lumme et al., 
2016; Osby et al., 2016; Saha et al., 2007). However, studies have also 
reported decreasing differences in mortality between people with SMI and 
the general population in Finland, Denmark and Sweden (Wahlbeck et al., 
2011; Westman et al., 2012). In an Australian study, cancer patients with SMI 
received less surgical treatment and chemotherapy than patients without 
SMI (Kisely et al., 2013). Similarly, a recent Finnish study showed that 
cancer mortality increased in people with SMI and was partly explained by 
poorer quality of treatment (Manderbacka et al., 2017). The less intensive 
treatment received by people with SMI is not limited to cancer. In a Finnish 
study, examining access to coronary care in people with psychotic disorders 
in 1998-2009, people with psychotic disorders had particularly poor access 
to hospital treatment for coronary heart disease and revascularization 
treatment (Manderbacka et al., 2012). In addition, medication use for 
cardiovascular disease has been observed to be lower in patients with 
schizophrenia than in the general population (Laursen et al., 2014). 
As described above, various factors increasing mortality risk accumulate 
for people with psychotic disorders and other SMI. These include lifestyle-
related factors, potential intrinsic factors to SMI and shared genetic risk 
between physical disease and SMI (Andreassen et al., 2013). Antipsychotic 
treatment further increases unfavourable metabolic changes resulting in a 
systemic inflammation.  
Antipsychotics have adverse effects that result in increased risk of 
cardiovascular disease and diabetes, as reviewed above. A systematic review 
consisting of 12 studies concluded that long-term exposure to antipsychotics 
increased mortality in schizophrenia, although the heterogeneity in the 
methods, follow-up times and outcomes in the individual studies was evident 
(Weinmann et al., 2009). Register-based studies from Finland and Sweden, 
investigating the association between antipsychotic use and mortality in 
schizophrenia, have found higher mortality risk in the groups with no 
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exposure to antipsychotics (Tiihonen et al., 2009; Torniainen et al., 2015). 
Specifically, antipsychotic, but also antidepressant, use has been associated 
with lower mortality in schizophrenia, whereas exposure to benzodiazepines 
may increase mortality (Tiihonen et al., 2016). In a Finnish study, 
antipsychotic use was not associated with mortality in people with 
schizophrenia (Suvisaari et al., 2013). However, in people over 65 years 
without a primary psychotic disorder antipsychotic use was associated with 
increased mortality (Suvisaari et al., 2013), concordant with the finding of 
increased mortality in people with dementia using antipsychotics (Koponen 
et al., 2017). In a recent study using Finnish register data, mortality in people 
hospitalized due to first-episode schizophrenia was higher during the 16.4-
year follow-up in those who discontinued antipsychotic medication within 
the first year after the first hospitalization compared to those using 
antipsychotics continuously (HR 2.74, 95% CI 1.09–6.89) (Tiihonen et al., 
2018). Mortality was even higher among patients who never used 
antipsychotics after the first hospitalization (HR 3.14, 95% CI 1.29–7.68).  
In studies examining mortality in FEP, unnatural cause mortality for 
suicides and accidents is higher than natural cause mortality, which is 
understandable given that the onset of FEP is typical in young adulthood 
when deaths due to natural causes are rare. The lifetime risk of suicide in 
psychotic disorders has been estimated to be 5.6%, and the highest risk is 
during the first year of treatment during which 10% of patients attempt 
suicide (Nordentoft et al., 2015). In the ÆSOP-10 study, 557 patients with 
FEP from Southeast London and Nottinghamshire, UK, were followed for 10 
years. Suicide was the leading cause of death; a 20-fold increase compared to 
the local general population. Unnatural cause mortality was in total 13-fold 
higher and natural cause mortality 2-fold higher than in the general 
population (Reininghaus et al., 2015). Interestingly, a study based on Danish, 
Finnish and Swedish register data found that the observed/expected ratio of 
natural cause mortality was also highest during the first year after first 
hospitalization due to a psychiatric disorder (Nordentoft et al., 2013).  
2.10 SUMMARY OF THE LITERATURE REVIEW 
Psychotic disorders are accompanied by substantial physical comorbidity and 
excess mortality. Although it seems that individuals with FEP do not differ 
from the general population of the same age in terms of weight or waist 
circumference, some metabolic risk factors, such as disturbances of glucose 
metabolism and elevated triglyceride levels, may already be present in drug-
naïve individuals with FEP. However, weight gain and increase in metabolic 
and cardiovascular risk factors, including glucose, insulin and lipid levels, is 
substantial after the initiation of antipsychotic medication. It is currently not 
possible to accurately predict which individuals will suffer most from the 
adverse metabolic effects of antipsychotics.  
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There is meta-analytic evidence of increased CRP in psychotic disorders. 
This increase has been observed in early psychosis as well as in chronic 
disease. There are a multitude of potential confounding factors when 
measuring CRP in psychosis, including obesity, stress, smoking and 
antipsychotic medication, which should be considered. Furthermore, the 
longitudinal course of pro-inflammatory activity marked by CRP is unknown 
in psychotic disorders.  
The mortality in psychotic disorders is increased compared to the general 
population, and this is mostly due to natural causes. The excess mortality in 
psychotic disorders, i.e. the mortality gap between people with psychosis and 
the general population, has not been decreasing during the last decades. 
Under-diagnosis and poor quality of treatment of physical comorbidities may 
be some reasons underlying the excess mortality in psychotic disorders. Even 
though antipsychotics increase the risk of some physical comorbidities, their 















3 AIMS OF THE STUDY 
The aim of the study was to clarify baseline differences between FEP patients 
and controls, and longitudinal changes during a 12-month follow-up in FEP 
patients in anthropometric measures (weight, waist circumference), 
metabolic parameters (glucose homeostasis, lipid levels) and low-grade 
inflammation. This study also aimed to investigate mortality in psychotic 
disorders, and to clarify the effect of sociodemographic status, physical 
disease, lifestyle-related factors, smoking and antipsychotic medication on 
mortality risk. 
 
Specific aims of the studies were: 
 
I. To identify baseline risk factors for changes in weight and waist 
circumference in FEP patients during a 12-month follow up. 
 
II. To examine baseline differences in anthropometric and metabolic 
measures between FEP patients and controls, and changes in the 
measures during a 12-month follow-up. Furthermore, baseline 
differences and longitudinal changes in low-grade inflammation 
measured by hs-CRP were investigated, with the aim of detecting 
factors associated with low-grade inflammation. 
 
III. To identify predictors of mortality in people with psychotic 
disorders during a 13-year follow-up, and to examine associations 
between previously known sociodemographic and health-related 




4.1 HELSINKI EARLY PSYCHOSIS STUDY (STUDIES I & 
II) 
4.1.1 STUDY DESIGN AND SUBJECTS 
The subjects in the Helsinki Early Psychosis Study were FEP patients 
between 18-40 years receiving their first treatment due to psychosis. They 
were recruited from the catchment areas of the Helsinki University Hospital 
and Helsinki Psychiatric Services from December 2010 to June 2016. 
Receiving a score of at least 4 in Unusual thought content or Hallucinations 
in the Brief Psychiatric Rating Scale–Expanded (BPRS-E) (Ventura et al., 
1993) and fluency in Finnish language were used as inclusion criteria to the 
study. Patients with substance-induced psychotic disorders and psychotic 
disorders due to a general medical condition were not included. 
Controls matched by age, gender and region of residence were identified 
from the Population Register Centre. Controls were assessed at baseline and 
at 12 months using the same protocol as described for the patients. The 
exclusion criteria for controls were lifetime history of psychotic disorder, 
chronic neurological, endocrinological or cardiovascular disease, or any 
condition that prevents magnetic resonance imaging (MRI).  
 Patients were assessed three times. The baseline assessment was done 
after the patient had entered treatment and as soon as the patient was able to 
give informed consent. The follow-up assessments were done at two and 12 
months after the baseline assessment. The number of participants and the 
psychiatric diagnoses of FEP patients in Studies I and II are shown in Table 5 
and 6. Table 7 shows the measures and scales used in the evaluation of FEP 
patients in each assessment. MRI using a 3 Tesla scanner was done at 
baseline and at 12-month follow-up for patients and controls (Mäntylä et al., 
2015). Blood and stool samples were collected from patients and controls at 
each assessment. Psychiatric diagnostic interviews were done at the follow-
ups of two and 12 months. The diagnostic assessments were based on the 
Research Version of the Structured Clinical Interview for DSM-IV Axis I 
Disorders (SCID-I) (First et al., 2002) and available medical records. After 
the interview, the interviewer confirmed the diagnosis with a senior 
psychiatrist. If there was uncertainty, three senior psychiatrists determined a 
consensus diagnosis.  
The study protocol was approved by the Ethics Committee of the Hospital 
District of Helsinki and Uusimaa (257/12/03/03/2009) and by the 
institutional review boards of the National Institute for Health and Welfare, 
Helsinki, Finland, and the University of Helsinki. All participants gave a 
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written informed consent. The treating psychiatrist assessed the patient’s 
capacity to give informed consent.  
4.1.2 MEASUREMENT OF HEIGHT, WEIGHT, WAIST 
CIRCUMFERENCE AND BLOOD PRESSURE 
A wall-mounted stadiometer was used to measure height. Weight was 
measured by using a standard portable scale. At baseline and at 12 months, 
the same scale was used (OBH Nordica 6251). At the 2-month follow-up, a 
scale in the treating clinic or at the National Institute for Health and Welfare 
was used, depending on the location of the interview.  
Waist circumference was measured during light expiration with a flexible 
tailor’s measuring tape while the subject was in a standing position with the 
legs slightly apart. The measuring tape was positioned at the midpoint 
between the lowest rib bone and the high point of the iliac crest. 
            The interviewer measured blood pressure after a five-minute rest 
using Omron M6 Comfort digital blood pressure monitor.  
4.1.3 MEASURES OF PHYSICAL ACTIVITY, DIET AND SMOKING 
The Gothenburg scale (Wilhelmsen et al., 1972) was used to measure the 
physical activity of the study subjects. The participants were asked how much 
they exercised or strained themselves. Participants were classified physically 
active when they reported: 1) walking, bicycling or otherwise moving at least 
four hours per week; or 2) exercising at least three hours per week; or 3) 
training for competitive sports. Otherwise participants were classified as 
having a sedentary lifestyle. 
Consumption of different foods and drinks during the past week was 
assessed using a questionnaire from the Health Behaviour and Health among 
the Finnish Adult Population survey (Helldán et al., 2013; Männistö et al., 
2010). The answers ranged from “not at all” (0 points) to “on 6-7 days” (3 
points). For assessing unhealthy diet, a sum score of the frequency of 
consumption of high-energy foods and drinks rich in fat and/or sugar (pizza, 
hamburgers, chocolate and sweets, cookies, pastries, juices and beverages 
containing sugar) was calculated. 
Current smoking was defined as current, regular smoking and having 









               














































































































































































































































































































































































































Schizophrenia   
Study I 24/60 40 




Study I 13/60 22 
Study II 22/95 23 
Psychotic disorder not 
otherwise specified 
  
Study I 11/60 18 
Study II 19/95 20 
Bipolar disorder with 
psychotic features 
  
Study I 7/60 12 
Study II 8/95 8 
Major depressive disorder 
with psychotic features 
  
Study I 0/60 0 
Study II 4/95 4 
Schizoaffective disorder   
Study I 2/60 3 
Study II 3/95 4 
Brief psychotic disorder   
Study I 2/60 3 
Study II 3/95 3 
Delusional disorder   
Study I 1/60 2 
Study II 1/95 1 
 
4.1.4 DEFINITIONS OF CLINICALLY SIGNIFICANT WEIGHT GAIN, 
OVERWEIGHT, OBESITY AND METABOLIC SYNDROME 
As per the criteria defined by the World Health Organization, BMI 
≥25.0kg/m2 was defined as overweight and BMI ≥30.0kg/m2 as obesity.  
For MetS, the IDF criteria were applied: MetS was diagnosed when the 
participant had elevated waist circumference (≥94cm in men and ≥80cm in 
women) and met at least two of the following criteria: triglycerides 
≥1.7mmol/L, HDL <1.03mmol/L in men and <1.29mmol/L in women, blood 
pressure ≥130/85mmHg, fasting glucose ≥5.6mmol/L (Zimmet et al. 2005). 
Clinically significant weight increase was defined as 7% increase from the 
baseline weight, in accordance with the definition of the Food and Drug 
Methods 
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Administration for clinically significant weight increase for studies of 
psychotropic medication (Sachs and Guille 1999). 
4.1.5 LABORATORY ANALYTICAL METHODS 
A fasting blood sample was collected between 8 and 10 am. Serum and 
plasma samples were immediately aliquoted and stored at −80oC. Serum 
total cholesterol, HDL cholesterol, triglycerides, hs-CRP, insulin, 
apolipoprotein A-I and apolipoprotein B (ApoB), and plasma glucose were 
measured on an Abbott Architect ci8200 analyser (Abbott Laboratories, 
Abbott Park, IL, USA) in the laboratory of the Genomics and Biomarkers 
Unit at the National Institute for Health and Welfare. The laboratory has 
been accredited by the Finnish Accreditation Service and it fulfills the 
requirements of the standards SFS-EN ISO/IEC 17025:2005. 
HOMA was used to assess insulin resistance (Muniyappa et al., 2007). 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2 THE HEALTH 2000 SURVEY AND THE PSYCHOSES 
IN FINLAND STUDY (STUDY III) 
The sample in the Finnish Health 2000 survey consisted of 8028 persons 
aged 30 years or older. A two-staged stratified cluster sampling procedure 
was used to get a nationally representative sample (Heistaro, 2008). The 
sampling frame was regionally stratified according to the five university 
hospital regions of Finland. Sixteen healthcare districts were sampled from 
each five regions as clusters, i.e. overall 80 healthcare districts, including 160 
municipalities. The 15 largest cities in Finland were included in the sample, 
the other 65 areas were selected by systematic probability proportional to 
population size sampling in each stratum. The persons were selected from 
the areas by systematic sampling, also including institutionalized and 
homeless persons. Oversampling (2:1) was used for persons over 80 years of 
age within the clusters to make sure that the oldest participants were 
adequately covered. 
The data were collected in the time period between September 2000 and 
June 2001. The fieldwork consisted of a home interview, a health 
examination (or for those unable to attend a health examination at a local 
healthcare centre, a condensed interview and health examination at home) 
and a telephone interview or mailed questionnaire for the remaining 
participants.  
Altogether, 93% (7419) of subjects contacted at the first phase of the 
survey participated in at least one study phase (Aromaa and Koskinen, 
2004).   
4.2.1 MENTAL HEALTH ASSESSMENT 
During the health examination the physician assessed whether the 
participant had a probable or definite psychotic disorder. Further, 
questionnaires and the Munich Version of the Composite International 
Diagnostic Interview (M-CIDI) (Wittchen et al., 1998) were used to assess 
mental disorders. The Finnish version of M-CIDI is computerized and a fully 
structured interview assessing 12-month diagnoses of mood, anxiety, 
psychotic and substance use disorders, and, in addition, lifetime diagnoses of 
alcohol/other substance dependence and psychotic experiences (Pirkola et 
al., 2005b).  
A second phase study, Psychoses in Finland (PIF) was conducted to 
confirm psychotic diagnoses in those screened in the Health 2000 study as 
having a probable psychotic diagnosis (Perälä et al., 2007). Psychotic 
diagnoses were screened based on either self-reported psychotic disorder, 
probable psychotic disorder as assessed by the physicians conducting the 
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health examination or psychotic or manic symptoms reported in the 
questionnaires used in the Health 2000 survey and the M-CIDI. In addition, 
information from the healthcare registers was used to complement the 
screening: hospital treatment due to psychotic disorder according to the 
Hospital Discharge Register, reimbursement for outpatient antipsychotic 
medication, disability pension due to psychotic disorder and mood stabilizing 
medication without a diagnosis of epilepsy or other neurological disease.  
Those with a probable psychotic diagnosis were assessed with the SCID-I 
interview. Lifetime case notes for psychiatric problems were also collected, as 
well as for those who did not take part in the SCID-I interview. Final best 
estimate diagnoses were made utilizing the information from the SCID-I 
interview and the case notes.  
The ethics committees of the National Public Health Institute (the 
National Institute for Health and Welfare since 2009) and the Hospital 
District of Helsinki and Uusimaa approved the Health 2000 Survey 
(407/E3/2000) and the PIF study (644/E3/2001). Participants gave a 
written informed  consent. 
4.2.2 STUDY POPULATION 
In Study III, persons aged 70 years and over, and persons with substance use 
disorder or psychotic disorder due to a general medical condition were 
excluded. The age restriction was made due to the high mortality of the 
oldest age groups, potentially confounding the analysis. Of the original study 
sample of persons aged less than 70 years (n=6334), 89.1% (n=5642) had 
participated in the Health 2000 study and were followed up in Study III. 
Non-response was corrected by weighting. 
Study III focused on people with non-affective psychosis (NAP) (Figure 1). 
Predictor analysis was not possible for people with affective psychoses due to 
no deaths in that group of people aged less than 70 years.  
 
 




4.2.3 PREDICTORS OF MORTALITY 
4.2.3.1 Antipsychotic medication 
Antipsychotic medication use was coded at study baseline based on the self-
reported medication use by the participants. They brought prescriptions or 
medications to the interview to assist in recording the medication use. 
4.2.3.2 Socioeconomic factors 
Information on family income was determined from the registers of the 
Finnish Tax Administration. Family income was divided into quintiles and 
adjusted for family size. Marital status at baseline was coded as married or 
cohabiting, or unmarried (including divorced, never-married or widowed). 
4.2.3.3 Lifestyle and health-related variables 
BMI was calculated as weight divided by height squared (kg/m2). Smoking 
was coded based on self-report of the participants as current smokers and 
non-smokers. Current smoking was defined as having smoked at least 100 
cigarettes during lifetime, regular smoking during the past year and most 
recently during the past month. 
4.2.3.4 Chronic physical disease 
The WHO 1999 criteria was used to diagnose T2D (World Health 
Organization Expert Committee, 1999). Diagnosis was based on self-reported 
diagnosis of T2D, confirmed in the clinical examination; antidiabetic 
medication use reported by the participant or according to the National 
Prescription Register of the Social Insurance Institution; reimbursed 
antidiabetic medication because of T2D according to the Medication 
Reimbursement Register of the Social Insurance Institution. 
Coronary heart disease (CHD) was diagnosed based on health 
examination, electrocardiogram and register data (Kattainen et al., 2006). 
MetS was diagnosed based on the National Cholesterol Education 
Program’s Adult Treatment Panel III criteria (Expert Panel on Detection 
Evaluation and Treatment of High Blood Cholesterol in Adults, 2001), 
requiring a minimum of three of the following: 1) central obesity (waist 
circumference >102cm in men and >88cm in women); 2) high fasting 
triglycerides (≥1.7mmol/l); 3) low HDL cholesterol (<1.03mmol/l in men and 
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<1.29mmol/l in women); 4) elevated systolic blood pressure (systolic blood 
pressure ≥130mmHg or diastolic pressure ≥85mmHg) and 5) impaired 
fasting glucose (≥6.1mmol/l).  
4.2.3.5 Low-grade inflammation 
Categorical variable based on the highest quintile of CRP concentration 
(2.43mg/l) was used to mark low-grade inflammation. 
4.2.4 MORTALITY AND CAUSES OF DEATH 
 
Information on mortality and causes of death were obtained from the Cause 
of Death statistics kept by Statistics Finland (up to December 31st 2013). The 
cause of death is determined by the treating physician if the cause is known, 
and in cases of unknown or suspected unnatural causes of death an autopsy 
is performed. As the forensic autopsy rate is high in Finland, the Cause of 
Death statistics can be considered reliable (Lunetta et al., 2007).  
Causes of death were classified into natural causes (ICD-10 A00–R99), 
including alcohol-related diseases and accidental poisoning by alcohol (F10, 
G312, G4051, G621, G721, I426, K292, K70, K852, K860, O354, P043, Q860, 
X45), and unnatural causes, including suicide (X60–X84, Y870) and other 
unnatural causes (V01–X44, X46–X59, X85–Y86, Y871–Y89). 
4.3 STATISTICAL METHODS 
In Studies I and II, most of the variables were non-normally distributed. 
Thus, descriptive statistics for sociodemographic and clinical variables were 
calculated using Pearson’s χ2 (or Fisher’s exact test) or Mann-Whitney U test 
in between-group comparisons. In Study III, Student’s t-test was used for 
comparisons of continuous variables. To test differences between baseline, 2-
month and 12-month follow-up measures in patients (Studies I and II), 
Friedman’s ANOVA (for continuous variables) and McNemar’s and 
Cochran’s Q tests (for categorical variables) were used. Alpha level for 
statistical significance was set at <0.05. Bonferroni correction was used to 
adjust the p-values for post hoc pairwise tests conducted after Friedman’s 
ANOVA and Cochran’s Q tests. SPSS statistical software versions 23 and 24 
were used for statistical comparisons. 
4.3.1 STUDY I 
General linear regression models were used to examine predictors of change 
in weight and waist circumference among FEP patients. First, correlations 
 
71 
between continuously or ordinally distributed variables and change in weight 
and waist circumference were calculated using the Spearman’s rank order 
correlation. For categorical variables, median change in weight and waist 
circumference was compared across the categories using the Mann-Whitney 
U test. Next, variables that were significantly associated with change in 
weight or waist circumference were chosen for general linear models which 
were calculated using PROC GLM in SAS statistical software. Shapiro-Wilk 
test was used to check if the assumption of normally distributed residuals 
held. There were two patients with pre-existing diabetes who were both 
excluded from the regression analysis. 
4.3.2 STUDY II 
To examine which variables were associated with longitudinal changes in hs-
CRP, mixed-effects regression modelling was used. Advantages of mixed-
effects models in a study with repeated measures include: 1) accounting for 
the correlation of repeated measures observations, and 2) the variability in 
time between assessments for each subject. Furthermore, 3) time-dependent 
covariates can be used, and 4) data with different number of repeated 
measurements for each subject can be analysed (Gueorguieva and Krystal, 
2004).  
For the mixed-effects models in Study II, hs-CRP was logarithm-
transformed to reduce the skewness of its distribution. Since the focus was 
on chronic low-grade inflammation hs-CRP values ≥10mg/l, indicative of 
acute infection, were excluded. Bayesian information criterion (BIC) 
(Schwarz, 1978) was used to select the variables for the model. BIC gives an 
estimate of how well the model fits the data and includes a penalty for the 
number of predictor variables in the model to avoid overfitting. Waist 
circumference and BMI were analysed as time dependent, as there were 
marked changes in them over the study period. Information on smoking 
status was used only from baseline, as there were few patients that either 
started or quitted smoking during the follow-up, and there were fewer 
missing data on smoking at baseline. Other variables that were considered as 
possibly associated with hs-CRP were insulin, HOMA, clozapine and 
olanzapine use and cannabis use.   
The final model included a random intercept for each patient. As the fixed 
effects, gender, time of assessment (days from baseline measurement), 
antipsychotic use at each assessment, baseline cigarette smoking and waist 
circumference were included. The analysis was run using PROC MIXED in 
SAS statistical software. 
4.3.3 STUDY III 
The sampling design of Health 2000 survey was taken into account in the 
statistical analyses, and post-stratification weights were used to adjust for 
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non-response. Seven Cox’s proportional hazards regression models, all 
adjusted for age and gender, were built to examine the effects of different 
variables on mortality using SUDAAN software’s SURVIVAL procedure. The 
explanatory variables in each model are presented in Table 8. All-cause 
mortality and mortality from disease and medical conditions were analysed 
separately. For the final model (Model VII), the proportional hazards 
assumption was checked by running the Kolmogorov-type supremum test 
with SAS’s PHREG procedure. The test indicated that the proportional 
hazards assumption held for all variables. 
In people with NAP, predictors of mortality were analysed with Cox’s 
proportional hazards model using SAS’s PHREG procedure. Due to the small 
number of cases in the NAP group (n=106), sampling design was not taken 
into account. Explanatory variables were the same as presented for Model 
VII, except for CHD because the number of cases was small. All-cause 








Table 8. Explanatory variables used in Cox’s regression models (Study III)a 
Model I Diagnosis of NAP 
Model II NAP + antipsychotic medication 
Model III Variables in Model II + low-grade 
inflammation 
Model IV Variables in Model II + marital status + 
income 
Model V Variables in Model II + BMI + smoking 
Model VI Variables of Model II + T2D + MetS + 
CHD 
Model VII All variables used in Models I-VI 
BMI, body mass index; CHD, coronary heart disease; MetS, metabolic syndrome; 
NAP, non-affective psychosis; T2D, type 2 diabetes 





5.1 PREDICTORS OF WEIGHT GAIN AND WAIST 
CIRCUMFERENCE INCREASE IN FIRST-EPISODE 
PSYCHOSIS (STUDY I) 
5.1.1 CHARACTERISTICS OF STUDY PARTICIPANTS 
Blood sample data were available for 60 FEP patients and 27 controls at the 
study baseline. At two and 12 months, the number of blood samples from 
patients was 43 and 22 (72% and 37% of the baseline sample), respectively. 
At 12 months, weight and waist circumference measurements were 
respectively available from 33 and 34 patients. No statistically significant 
differences in age, symptom severity, anthropometric measures or laboratory 
values were found between patients followed during the whole study period 
and those who dropped out, either during the study or were recruited less 
than 12 months before the data was analysed.  
Patients had lower education, were more often unemployed and had a 
more sedentary lifestyle at baseline compared to controls (Table 9). 
Otherwise patients and controls were similar in terms of potential 
confounding factors. There were no differences in baseline BMI or waist 
circumference between patients and controls (Table 10). 
At baseline, olanzapine and risperidone were each prescribed to 37% of 
patients (n=22), quetiapine to 23% (n=14) and other antipsychotics to 22% of 
patients (n=13). Eight percent of patients (n=5) were not using 
antipsychotics at baseline. The median duration of antipsychotic use at 
baseline was 26 days. 
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Table 9. Baseline demographic and clinical variables in FEP patients and controls  
 FEP patients (n=60) Controls (n=27) P-valuea 
Age 
 
24.5 (21.5, 29.5) 25.0 (23.3, 33.9) 0.183 
Male 
 
39/60 (67%) 13/27 (48%) 0.138 
Living with parents 
 
19/60 (32%) 3/27 (11%) 0.041 
No vocational or 
higher education 
 




38/60(63%) 26/27 (96%) 0.001 
Smoking 
 
16/51 (31 %) 4/25 (16 %) 0.153 
No illicit substance 
use lifetime 
 
29/56 (52 %) 17/25 (68 %) 0.174 
Active lifestyleb 
 





4 (0-9) 4 (1-7) 0.634 
Positive symptomsd 
 
7 (4, 10) 0 (0, 0) <0.001 
Negative symptomse 
 
5 (3.25, 9.0) 0 (0, 0) <0.001 
AUDIT 
 
6 (2, 13) 6 (3, 7) 0.646 
GAF 35 (30, 40) 85 (75, 90) <0.001 
 
AUDIT Alcohol use disorder identification test, BMI Body mass index, GAF Global 
assessment of functioning scale 
aContinuous variables: Mann-Whitney U test. Categorical variables: chi-squared test.  
bEasy exercise at least 4 hours per week, self-reported 
cSum score of the frequency of consumption of high-energy foods and drinks rich in fat 
and/or sugar (pizza, hamburgers, chocolate and sweets, cookies, pastries, juices and 
beverages containing sugar) 
dSum score of BPRS-E items 10 (hallucinations), 11 (unusual thought content), 12 (bizarre 
behavior) and 15 (conceptual disorganization) 









5.1.2 CHANGES IN ANTHROPOMETRIC MEASURES DURING 
FOLLOW-UP  
The median waist circumference increased 6.0cm from baseline to the 12-
month assessment (baseline 84cm [IQR 79-89cm], 12-month 90cm [IQR 
84–96cm], p<0.001) in FEP patients. BMI increased from 22.7kg/m2 (IQR 
20.9-25.6kg/m2) to 25.9kg/m2 (IQR 23.3-29.5kg/m2, p<0.001). Olanzapine 
medication at baseline (n=22) was associated with the greatest 12-month 
weight gain (mean 17.7kg [SD 8.7kg] in olanzapine users vs. 8.5kg [SD 6.9kg] 
in other patients, t=3.39, p=0.002). Weight change during the study period 
correlated statistically significantly with baseline unhealthy diet 
(Spearman´s rho 0.46, p=0.01) and positive symptoms (Spearman´s rho 
0.39, p=0.03). Change in waist circumference correlated with baseline 
insulin (Spearman´s rho 0.35, p=0.04) and positive symptoms (Spearman´s 
rho 0.35, p=0.04). Of categorical variables, olanzapine use and insulin 
resistance at baseline (defined as the highest quartile of HOMA due to the 
highly skewed distribution) were associated with weight gain (Table 11).  
 
Table 10. Anthropometric measures of FEP patients and controls at 
baseline 
Variable FEP patients Controls P-valuea 














79.0 (70, 87.5) 81.0 (72.0, 85.75) 0.761 








Table 11. Associations of baseline variables with change in weight and waist 




Weight change (kg) 
 
Change in waist circumference 
(cm) 
 Mean (SD) P-valuea Mean (SD) P-valuea 
Gender     
  Men 12.0 (7.7) 0.78 10.4 (7.7) 0.29 
  Women 11.6 (10.3)  7.5 (7.1)  
Olanzapine     
  Yes 17.7 (8.7) 0.003 12.0 (7.5) 0.13 
  No 8.5 (6.9)  7.6 (7.3)  
Sedentary lifestyle     
  Yes 11.1 (5.9) 0.98 11.8 (9.2) 0.19 
  No 11.4 (9.8)  7.5 (5.9)  
Insulin resistanceb     
  Yes 15.3 (6.8) 0.26 17.0 (7.4) 0.01 
  No 11.2 (9.0)  7.6 (6.6)  
a Mann-Whitney U test 









5.1.3 PREDICTORS OF CHANGE IN ANTHROPOMETRIC 
MEASURES DURING FOLLOW-UP 
Table 12 shows the p-values for the predictors of weight gain and waist 
circumference increase in the regression models for weight change and 
change in waist circumference. Olanzapine use and insulin resistance at 
baseline were statistically significant predictors for 12-month weight gain. 







Table 12. P-values and R2 for predictors in the regression models for weight 




Model 1: weight change 
 
Model 2: change in waist 
circumference 
Insulin resistance 0.025 0.0036 
Olanzapine use 0.0076 0.09 
Unhealthy diet 0.07 0.08 
Severity of positive 
symptoms 
0.20 0.72 





5.2 DEVELOPMENT AND PREDICTORS OF LOW-
GRADE INFLAMMATION IN FIRST-EPISODE 
PSYCHOSIS (STUDY II) 
5.2.1 CHARACTERISTICS OF STUDY PARTICIPANTS 
Altogether 97 FEP patients and 62 controls took part in the study at baseline. 
Two of the patients were diagnosed with a substance-induced psychotic 
disorder and were excluded from the analyses. Table 13 and Table 14 show 
the demographic and clinical characteristics of the participants. Of patients, 
93% (n=88) reported using antipsychotic medication at baseline. The median 
duration of antipsychotic medication at baseline was 22 days (IQR 10-49 
days) among the FEP patients. Olanzapine (n=35), risperidone (n=34) and 
quetiapine (n=18) were the most commonly prescribed antipsychotics at 
baseline. Figure 2 and Table 15 show the distribution of psychotropic 
medication used throughout the study period. Sixty per cent (n=57) of 































Table 13. Baseline clinical and demographic characteristics of all 95 first-episode 
psychosis (FEP) patients, FEP patients with 12-month follow-up data available (n=52) 
and 62 controls 
 FEP patients, n 






n (%), or 
median (25%, 
75%) 
Controls, n (%), 




Age 24.9 (21.6, 29.4) 25.4 (22.6, 
30.1) 
24.0 (21.7, 28.7) 0.828 
Male 65/95 (68%) 31/52 (60%) 40/62 (65%) 0.611 
Living with parents 35/95 (37%) 18/52 (35%) 10/62 (16%) 0.005 
No vocational or 
higher education 
38/95 (40%) 15/52 (29%) 11/62 (18%) 0.003 
Employed, military 
or student 
73/95 (77%) 41/52 (79%) 59/62 (95%) 0.002 
Smoking 20/78 (26%)  9/47 (19%) 11/53 (21%) 0.518 
No illicit substance 
use lifetime 
40/74 (54%) 27/45 (60%) 26/51 (51%) 0.735 




4.5 (0-9) (n=70) 4.5 (0-9) 
(n=44) 
4 (1-9) (n=51) 0.932 
Positive symptom 
scoree 
6 (3, 9) 6.5 (3, 9) 0 (0, 0) 0.001 
Negative symptom 
scoref 
5 (3, 8) 5 (3, 8) 0 (0, 0) 0.001 
AUDIT 5 (2, 12) (n=74) 4 (1, 12) (n=45) 6 (3, 9) 0.797 
GAF 35 (31, 40) 35 (30, 40) 86 (77, 90) 0.001 
AUDIT, Alcohol use disorder identification test; BMI, Body mass index; GAF, Global assessment of 
functioning scale 
aWith 12-month CRP available. bComparison of all FEP patients and controls. Mann-Whitney U test for 
continuous variables;  chi-squared test for categorical variables. cEasy exercise at least 4 hours per week, self-
reported. dSum score of the frequency of consumption of high-energy foods and drinks rich in fat and/or sugar 
(pizza, hamburgers, chocolate and sweets, cookies, pastries, juices and beverages containing sugar). eSum 
score of BPRS-E items 10 (hallucinations), 11 (unusual thought content), 12 (bizarre behavior) and 15 
(conceptual disorganization). fSum score of BPRS-E item 16 (blunted affect) and SANS-score 











Table 14. Body mass index and waist circumference measures of patients and controls 
at baseline (Study II) 





Body mass index 22.9 (21.1, 25.9)  23.0 (20.9, 
25.8)  
23.8 (21.8, 25.8) 0.356 
Waist circumference 
(cm; total) 
83.0 (78.0, 90.0) 82.5 (75.5, 
89.0) 
82.0 (77.0, 90.0) 0.519 
Waist circumference 
(cm; men) 
85.0 (81.0, 91.0) 84.0 (79.0, 
89.0) 
86.0 (78.0, 92.0) 0.443 
Waist circumference 
(cm; women) 
78.5 (69.8, 86.3) 79.0 (71.0, 
84.5) 
79.0 (72.8, 85.8) 0.584 











5.2.2 BASELINE METABOLIC AND ANTHROPOMETRIC 
MEASURES OF PATIENTS AND CONTROLS 
At baseline, FEP patients had increased HOMA, total and LDL cholesterol, 
triglycerides and ApoB compared to controls (Figure 3). There were no 
significant differences in baseline measures of weight, waist circumference, 
hs-CRP, fasting glucose or HDL cholesterol between patients and controls. Of 
patients, 11% (9/84) met the criteria for MetS. 
5.2.3 CHANGES IN METABOLIC MEASURES AND HS-CRP 
DURING FOLLOW-UP 
By the 12-month assessment, patients had gained a median of 9.6kg of 
weight (IQR 1.5-13.6kg) and their waist circumference had increased by a 
median of 6.0cm (IQR 2.0-13.0cm). Forty of 59 patients (68%) had gained 
>7% of weight, a threshold considered clinically significant weight gain. The 
proportion of patients who had lost weight was 14% (n=8/59); range of 
weight loss was 0.2-3.5kg. The prevalence of MetS from baseline to the 12-
month assessment rose from 11% (9/84) to 19% (10/53), which was not 
statistically significant. Apart from the increase in the proportion of patients 
meeting the criterion for elevated waist circumference (Figure 4, baseline to 
Table 15. Prevalence of antipsychotic monotherapy and mood-stabilizing medication in 
FEP patients 
 Baseline (n=95) Two months (n=77) 12 months (n=61) 
Antipsychotic 
monotherapy 
78 (88%)a 61(86%)a 38 (81%)a 
Lithium 2 (2%) 2 (3%) 1 (2%) 
Valproate 2 (2%) 3 (4%) 5 (8%) 
Lamotrigin 2 (2%) 1 (1%) 2 (3%) 
Antidepressant 19 (20%) 22 (29%) 19 (31%) 




2-month to 12-month: 27% [26/95]; 44% [34/77]; 54% [32/59], χ2=21.444, 
p<0.001) the proportion meeting the criteria for other components of MetS 
did not increase significantly during the follow-up. 
Those FEP patients who were using antipsychotics at the 12-month 
assessment had a median weight gain of 10.8kg (IQR 4.0-14.4), whereas 
those who were antipsychotic-free at the 12-month assessment gained 5.6kg 
(-1.7 to 10.0kg, U=201.5, p=0.043). The respective median changes in waist 
circumference during the 12-month study period were 1.0cm (IQR -1.0 to 
7.0cm) and 8.5cm (IQR 4.0-15.3cm, U=160.5, p=0.011). 
Hs-CRP increase during the study period was statistically significant in 
patients (Figure 5): baseline (median) 0.67mg/l (IQR 0.33-2.54mg/l); 2-



















































































   



































5.2.4 PREDICTORS OF HS-CRP DURING THE FOLLOW-UP 
In the final mixed-effects regression model analysis, waist circumference 
(β=0.05048, standard error [SE]=0.006646, p<0.0001) and female gender 
(β=0.4721, SE=0.1882, p=0.0140) were statistically significant predictors of 
higher logCRP (Table 16). Other variables used in the final model contributed 
to the model fit based on the BIC, but they did not reach statistical 
significance as predictors of logCRP. Other tested variables were not included 
in the model, as they were not significantly associated with logCRP and did 
not improve the model fit assessed by the BIC. 
Replacing waist circumference with BMI as a predictive variable 
decreased the model’s goodness of fit, but BMI was also a significant 



























Table 16. Estimates, standard errors and p-values of the 
variables used in the final mixed-effects regression model 









Intercept -4.4968 0.6291 <0.0001 
Waist 
circumference 
0.05048 0.006646 <0.0001 
Female gender 0.4721 0.1882 0.0140 
Time from 
baseline (days) 
0.000328 0.000403 0.4179 
Smoking at 
baseline 




0.3365 0.2382 0.1614 
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5.3 MORTALITY IN NON-AFFECTIVE PSYCHOSIS 
(STUDY III) 
As there were no deaths in the affective psychosis group, analysis on 
mortality was done in the non-affective psychosis group (n=106). There were 
25 deaths in the NAP group during the 13-year follow-up period. Cancer and 
cardiovascular disease were the most common causes of death, and 
altogether natural causes made up 84% (21/25) of all deaths (Figure 6). 
In the NAP group, those who died during the follow-up were older (55.9, 
SD 9.3 vs. 48.8, SD 10.0, p=0.002), less often married or cohabiting (16% vs. 
40%, p=0.03) and had a higher prevalence of T2D (36% vs. 12.3%, p=0.014) 
compared to those who survived.  
In people diagnosed with NAP, the all-cause mortality hazard ratios (HR) 
ranged from 2.11 (95% CI 1.10-4.05) when adjusting for all relevant variables 
(age, gender, smoking, socioeconomic factors, antipsychotic use, CRP level, 
obesity, T2D, MetS and CHD) to 2.99 (95% CI 2.03-4.41) when adjusting 
only for age and gender (Figure 7).  
HR for natural cause mortality among people with NAP did not reach 
significance when adjusting for all the relevant variables (HR 1.98, 95% CI 
0.94-4.16), but was significantly elevated in all the other models (Figure 7). 
In people with NAP, those who used antipsychotics at baseline had a 
reduced HR for natural cause mortality (HR 0.25, 95% CI 0.07-0.96). 
Smoking was associated with increased HR for natural cause mortality in 














Figure 7. Cox proportional hazard models for all-cause and natural cause mortality hazard 
ratios (HR) in people with non-affective psychosis (n=106) adjusted with a different set of 
variables in each model I-VII. Solid horizontal line marks the mortality HR in the general 
population used as reference 
 
 
Cox proportional hazard models presented in Figure 7 were adjusted for age 
and gender as well as in addition for the following variables: 
Model I: diagnosis of NAP 
Model II: NAP + antipsychotic medication 
Model III: Model II + low-grade inflammation 
Model IV: Model II + socioeconomic factors (marital status and income)  
Model V: Model II + lifestyle-related factors (BMI and smoking) 
Model VI: Model II + chronic physical disease (T2D, MetS and CHD) 
Model VII: All variables from models I-VI 
 





6.1 SUMMARY OF THE MAIN FINDINGS 
Although FEP patients did not differ from healthy controls in BMI or waist 
circumference at baseline, remarkable weight gain and increase of waist 
circumference were observed during the first treatment year of FEP (Studies 
I and II). Of antipsychotics, olanzapine was associated with the greatest 
weight gain. Insulin resistance and olanzapine use at study baseline were 
significant predictors of weight gain during the first treatment year of FEP, 
and insulin resistance at baseline predicted waist circumference change 
(Study I).  
At baseline, FEP patients had higher insulin, insulin resistance, total 
cholesterol, LDL cholesterol, triglyceride and apolipoprotein B levels than 
controls (Study II). There was no difference between FEP patients and 
controls in hs-CRP levels at baseline.  
A significant increase in hs-CRP was detected in FEP patients during the 
first treatment year, and this increase was predicted by waist circumference 
and female gender in a mixed-effects regression model (Study II). BMI was 
also a statistically significant predictor of hs-CRP, although waist 
circumference was a better predictor in terms of model fit. No changes were 
observed in glucose or lipid parameters during the first treatment year of 
FEP, despite the notable increases in weight and waist circumference. 
In a population sample, people with NAP had a 2-3-fold increased 
mortality risk during a 13-year observation period compared to the general 
population (Study III). The increased mortality was only partly explained by 
socioeconomic factors, cardiovascular and metabolic comorbidities, 
inflammation and lifestyle. Smoking was associated with increased natural 
cause mortality in NAP, while antipsychotic use was associated with reduced 
mortality risk. 
6.2 WEIGHT GAIN AND INCREASE OF WAIST 
CIRCUMFERENCE IN FEP 
No baseline differences were observed in weight, BMI or waist circumference 
between FEP patients and healthy controls. A rapid increase in weight and 
waist circumference was already evident at the 2-month measurement and 
continued until the 12-month measurement, in accordance with the literature 
describing significant risk of weight gain and abdominal obesity early in the 
treatment of FEP (Foley and Morley, 2011; Tek et al., 2016). The median 
weight gain of 9.6kg during the 12-month follow-up in Study II was of the 
same magnitude as in another study of 170 patients with FEP treated with 
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haloperidol, olanzapine or risperidone (Perez-Iglesias et al., 2014). The study 
by Perez-Iglesias et al. reported an increase of 10.3kg in mean weight during 
the first year of treatment, which constituted 85% of the total weight gain 
during a three-year follow-up (Perez-Iglesias et al., 2014). Another study, 
following patients with FEP for one year from the start of treatment, reported 
that patients using olanzapine throughout the study period (n=11) gained 
16.9kg in weight, risperidone (n=43) 7.5kg, haloperidol (n=24) 4.1kg and 
perphenazine 1.5kg, while patients not using antipsychotics gained 1.5kg in 
weight (Strassnig et al., 2007). In Study II, antipsychotic switches were 
common and thus differences in weight gain between different antipsychotics 
were not compared, but olanzapine also showed the greatest weight gain 
potential in this study.  
The prevalence of overweight and obesity approximately doubled from 
30% to 59% among FEP patients during the first treatment year. About two-
thirds of patients gained a clinically significant amount (>7%) of weight 
during 12 months. Similar percentages have been reported in the literature. 
In Strassnig et al. (2007), the proportion gaining >7% of weight was lower in 
those using FGA (38%) than in those using SGA (59%). Similarly, in a one-
year randomized controlled trial (RCT) comparing haloperidol, amisulpride, 
olanzapine, quetiapine and ziprasidone in FEP, the proportion of patients 
having >7% weight gain ranged from 37% (ziprasidone) to 86% (olanzapine), 
although the between-group differences were not statistically significant 
(Kahn et al., 2008). Another RCT reported that 80% of patients with FEP 
had >7% weight gain during 52 weeks of olanzapine medication, 58% of 
those using risperidone and 50% of those using quetiapine (Mcevoy et al., 
2007). 
Antipsychotic use was also associated with weight gain and increase in 
waist circumference in Study II; those who were using antipsychotics at the 
12-month assessment had an almost 2-fold increase in weight compared to 
those who were antipsychotic-free at the 12-month assessment, and the 
difference between medicated and non-medicated patients was even greater 
when comparing the increase of waist circumference. 
Interestingly, olanzapine was the most commonly prescribed 
antipsychotic in Studies I and II. Although olanzapine is efficient in treating 
psychotic symptoms (Leucht et al., 2013), concerns have been raised whether 
olanzapine is an appropriate choice as a first-line antipsychotic in FEP due to 
its harmful metabolic effects (Buchanan et al., 2010). These concerns may 
not have yet affected antipsychotic prescription patterns. For example, in a 
nationwide US sample consisting of 404 first-episode schizophrenia 
spectrum patients, 17% of antipsychotic prescriptions were for olanzapine, 
and, compared to other antipsychotics, olanzapine was prescribed more often 
in doses exceeding the recommended maximum dose (Robinson et al., 2015). 
In Study II, olanzapine was prescribed to over one third of the patients at 
baseline, and although this proportion diminished during the follow-up, 
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olanzapine was still the most prescribed antipsychotic at 12-month 
assessment.  
Olanzapine use at baseline was associated with the greatest weight gain in 
follow-up, but due to medication switches during the follow-up, no further 
analysis on the effects of specific antipsychotics on weight and waist 
circumference was done. A selection bias might affect the results of such 
analysis: those who were already overweight or obese at baseline may have 
been prescribed less olanzapine to avoid further metabolic harm. This is 
demonstrated by the fact that patients prescribed olanzapine at baseline 
showed a trend for lower baseline BMI (Mdn 22.7kg/m2) compared to those 
who were not prescribed olanzapine (Mdn 23.4kg/m2, p=0.10). Similarly, 
those who first gained a significant amount of weight with olanzapine may 
have had more switches to other antipsychotics with less weight gain 
potential. 
6.2.1 BASELINE PREDICTORS OF CHANGES IN WEIGHT AND 
WAIST CIRCUMFERENCE (STUDY I) 
In a linear regression model, insulin resistance and olanzapine use at 
baseline predicted weight gain during the 12-month follow-up, and insulin 
resistance at baseline, defined as HOMA in the highest quartile, predicted 
increase in waist circumference. In Study I, there were no differences 
between FEP patients and controls in glucose, insulin or HOMA at baseline. 
Insulin resistance as a predictor of weight gain and increase in waist 
circumference in FEP is a novel finding. In the general population, 
abdominal obesity has been associated with subsequent development of 
insulin resistance (Park et al., 2010). However, the reverse association (i.e. 
insulin resistance preceding the development of abdominal obesity) has also 
been reported (Sossa et al., 2013). Some longitudinal studies have reported 
higher insulin levels or insulin resistance predicting weight gain in the 
general population (Sigal et al., 1997; Tong et al., 2005). However, other 
studies have not found this association (Silver et al., 2006; Zavaroni et al., 
1998). In a study examining the metabolic risk of first-degree relatives of 
subjects with T2D, insulin resistance was superior to BMI or waist 
circumference in predicting MetS and overall metabolic risk, suggesting that 
in a genetically high-risk population, individuals with normal body weight 
who are insulin resistant have an increased metabolic risk compared to those 
who are obese but insulin sensitive (Utzschneider et al., 2010).  
Glucose metabolism may be intrinsically dysregulated in psychotic 
disorders, as indicated by a meta-analysis showing evidence of insulin 
resistance in antipsychotic-naïve individuals with FEP (Perry et al., 2016). 
Although the reason for the association between psychosis and impaired 
glucose metabolism is unclear, some potential explanations have been 
discussed in the literature. There is inflammatory activity associated with 
T2D and psychotic disorders, and inflammation may play a part in glucose 
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dysregulation in both diseases (Calle and Fernandez, 2012). Also, psychosis 
has been associated with hyperactivity of the hypothalamus-pituitary-adrenal 
axis, which is a system regulating endocrine responses to stress and, among 
other functions, has an important role in energy metabolism (Borges et al., 
2013). The higher level of circulating cortisol in patients with FEP could lead 
to disturbances in the glucose metabolism. Furthermore, people with 
psychotic disorders may have a genetic liability for insulin resistance and 
T2D. This is demonstrated by studies showing that T2D and schizophrenia 
share gene variants increasing the risk for both diseases (Hansen et al., 2011; 
Lin and Shuldiner, 2010). There is also evidence of increased risk of T2D in 
unaffected relatives of people with psychotic disorders (Mothi et al., 2015; 
Van Welie et al., 2013). A recent study found decreased insulin sensitivity 
both in FEP patients and their unaffected siblings compared to controls 
(Chouinard et al., 2018). The evidence suggests that the increased risk of T2D 
in schizophrenia is not only a consequence of poor health habits and 
antipsychotic medication, but may also be affected by shared genetic risk or 
factors intrinsic to schizophrenia. 
Most of the FEP patients in Study I were using antipsychotics at baseline 
with a median of 26 days of antipsychotic use. Antipsychotics have rapid 
effects on glucose metabolism, as shown by a meta-analysis examining the 
effects of antipsychotics on insulin resistance in healthy volunteers 
(Burghardt et al., 2018). A reduction in insulin sensitivity was observed in 
studies in which antipsychotics were administered for 3 to 13 days 
(Burghardt et al., 2018). Weight gain was detected only in studies of longer 
duration, probably because weight gain requires a more long-standing 
imbalance of energy intake and expenditure. In Study I, FEP patients with 
insulin resistance at baseline may have been especially vulnerable to 
antipsychotic-related metabolic dysregulation. It is also possible that patients 
who were adherent to medication displayed greater antipsychotic-induced 
insulin resistance early in the treatment and more weight gain in the longer-
term compared to those who had a lower adherence to medication. 
6.3 CHANGES IN GLUCOSE METABOLISM AND LIPIDS 
A somewhat surprising finding in Studies I and II was that the metabolic 
parameters of glucose and lipid levels did not change significantly during the 
follow-up in FEP patients. This is in contrast with several findings from 
studies showing increasing lipid, glucose and insulin resistance levels in FEP 
during the first year after treatment initiation (Fleischhacker et al., 2013; 
Foley and Morley, 2011; Perez-Iglesias et al., 2014). It is possible that the 
relatively short duration of antipsychotic use at baseline had already 
disturbed glucose and lipid metabolism, influencing the observed baseline 
differences in insulin resistance, non-HDL cholesterol and triglycerides.  
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An in vitro study indicated that antipsychotics have rapid effects on lipid 
metabolism by first inhibiting cholesterol biosynthesis, and then via a 
feedback mechanism, actually increasing the synthesis rate (Canfran-Duque 
et al., 2013). It is also possible that factors inherent to the psychotic illness 
result in disturbed lipid metabolism in FEP. According to two recent meta-
analyses, FEP patients with minimal or no exposure to antipsychotics show 
differences in lipid levels compared to controls (Misiak et al., 2017; Pillinger 
et al., 2017b). Intriguingly, both meta-analyses reported lower levels of total 
and LDL cholesterol and higher triglycerides in FEP compared to controls. 
The meta-analysis by Misiak et al. also found lower levels of HDL cholesterol 
in FEP, but this was not observed in the meta-analysis by Pillinger et al. 
(2017).  
These meta-analyses imply that dyslipidemia in chronic psychotic 
disorders results from factors such as sedentary lifestyle, poor diet and 
antipsychotic medication. The lower levels of total cholesterol and especially 
LDL cholesterol in FEP would signify lower cardiovascular risk, as LDL 
cholesterol is a major risk factor and also causal factor in cardiovascular 
disease (Ference et al., 2017). Pillinger et al. (2017) reported that in FEP the 
absolute reduction in total cholesterol was 0.26mmol/l, in LDL 0.15mmol/l, 
and an increase in triglycerides of 0.08mmol/l. The difference in LDL would 
translate to a cardiovascular risk reduction of 3% (Pillinger et al., 2017b). 
However, in Study II, total cholesterol, LDL and triglyceride levels were 
already higher in FEP patients at baseline. 
 
6.4 DEVELOPMENT OF LOW-GRADE INFLAMMATION 
IN FEP (STUDY II) 
In Study II, no baseline differences were observed between FEP patients and 
controls in hs-CRP. However, hs-CRP increased during the 12-month follow-
up over 2.5-fold. Analysed with mixed-effects models, waist circumference, 
BMI and female gender were significant predictors of hs-CRP levels. 
The finding of similar levels of low-grade inflammation measured by hs-
CRP at baseline between FEP patients and controls is not in agreement with 
meta-analyses published on CRP levels in psychotic disorders, which 
uniformly report higher CRP levels in psychosis, and two reported that 
increased BMI did not explain the association (Fernandes et al., 2016; Wang 
et al., 2017). In addition, the meta-analysis by Fernandes et al. analysed 
separately studies where participants were drug-naïve or drug-free, and 
concluded that CRP levels were still higher in this group than in healthy 
controls. However, of the six studies including only unmedicated individuals 
with early psychosis that were included in the meta-analysis, three did not 
show significant differences between patients and controls, while the other 
three studies displayed large effect sizes ranging from 1.45–1.91. The wide 
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range of effect sizes shows that there is high variability between individual 
studies.  
One factor potentially explaining some of the differences between 
individual studies is the selection of controls. In Study II, controls were 
recruited randomly from the general population with matching for age, 
gender and region of residence. There were no statistically significant 
differences between patients and controls at baseline in lifestyle factors, such 
as smoking and exercise, which could affect CRP levels (Fedewa et al., 2017; 
Ohsawa et al., 2005). If controls were to have healthier lifestyle habits than 
the average population, this could bias the comparison of CRP towards lower 
levels in controls. 
Waist circumference was a highly significant predictor of hs-CRP levels in 
the mixed-effects model of Study II. This is consistent with results from 
general population studies showing that obesity correlates strongly with CRP 
levels, and waist circumference more strongly than BMI (Choi et al., 2013). 
Adipose tissue is not only a storage for excess energy but has active endocrine 
functions. For example, adipocytes monitor the energy status and aim to 
maintain energy homeostasis by secreting hormones, e.g. leptin which 
reduces food intake. Adipocytes can also regulate lipolysis by activating the 
sympathetic nervous system (Reilly and Saltiel, 2017). When nutrients are 
abundant, adipocytes are under constant anabolic effects of insulin and other 
hormones. Eventually the expanded adipocytes reach a threshold after which 
an inflammatory activation takes place. The pro-inflammatory activation 
leads to an increase in cardiovascular risk and mortality, for which CRP is an 
independent risk factor (Emerging Risk Factors Collaboration et al., 2010; 
Ridker, 2016). It is thus of great concern, that young, originally metabolically 
healthy adults with FEP show not only significant weight gain and increase in 
abdominal obesity, but also a remarkable rise in hs-CRP, indicating a state of 
low-grade inflammation which further adds to their cardiovascular risk. 
Female gender was another statistically significant predictor of hs-CRP 
levels in the mixed-effects model. This is in agreement with findings of 
women having larger increases in CRP levels with increasing body fat mass 
compared to men (Cartier et al., 2009; Khera et al., 2009). This may be due 
to hormonal differences between women and men, e.g. oestrogens increasing 
the CRP concentration (Khera et al., 2009). Also, the hepatic CRP production 
may be stimulated more strongly by leptin in women (Hribal et al., 2014), as 
leptin levels have been shown to associate steeper with body fat parameters 
in women than in men (Abdullah et al., 2007). 
In Study II, patients had a median of 22 days of antipsychotic treatment 
before the baseline assessment. There is evidence of antipsychotics reducing 
the levels of pro-inflammatory cytokines and increasing the levels of anti-
inflammatory cytokines, thus attenuating pro-inflammatory activity 
(Fonseka et al., 2016; Tourjman et al., 2013). As reviewed by Baumeister et 
al. (2016), there is conflicting evidence from in vivo and in vitro studies and 
different studies showing opposing effects for same antipsychotics 
Discussion 
94 
(Baumeister et al., 2016). Nonetheless, the results of Study II suggest that if 
antipsychotics have anti-inflammatory effects, they are outweighed by the 
pro-inflammatory effect of increasing abdominal obesity. 
It should be noted, that apart from antipsychotics, other drugs may also 
affect CRP levels and confound the comparison of results between different 
populations. For example, valproate and antidepressants have 
immunomodulatory effects (Baumeister et al., 2016; Sinn et al., 2007), and 
statins lower the level of CRP independent of the drug’s effects on lipids 
(Devaraj et al., 2011).  
6.5 MORTALITY IN NON-AFFECTIVE PSYCHOSIS 
(STUDY III) 
In Study III, the all-cause mortality HR during a 13-year follow-up in NAP 
was 2.99 when adjusting for age and gender, and 2.1 when adjusting, in 
addition, for antipsychotic medication, socioeconomic factors, smoking, 
obesity, inflammation and chronic physical disease. The increased mortality 
was mostly due to natural causes, with cancer and cardiovascular disease 
accounting for over half of the all-cause mortality. Accidents and suicide 
accounted for 16% of the all-cause mortality. Smoking increased the 
mortality HR for natural causes while antipsychotic use decreased it. 
Similar increased mortality risk in psychotic disorders has been reported 
previously. A systematic review assessing mortality in schizophrenia reported 
a SMR of 2.58 for all-cause mortality (Saha et al., 2007). In a study based on 
Swedish register data, people with schizophrenia had increased mortality 
from ischaemic heart disease (adjusted HR [aHR] for women 3.3 and for 
men 2.2) and cancer (aHR women 1.7, men 1.4), as well as increased total 
and natural cause mortality (Crump et al., 2013b). In the US, a study 
including over 1.1 million individuals with schizophrenia calculated a SMR of 
3.7 for all-cause mortality (Olfson et al., 2015). In Finland, a study examining 
the Health 2000 sample up to September 2009 found that people with 
schizophrenia had a mortality HR of 3.0, and people with other NAP 1.8 
(Suvisaari et al., 2013). Another Finnish study, including people with 
schizophrenia older than 65 years, found that the mortality rate for unnatural 
causes of death was significantly higher (SMR 11.0) than the mortality for 
natural causes (SMR 2.6), reflecting the low rate of unnatural deaths in the 
general population of same age (Talaslahti et al., 2012).  
As the mortality HR in NAP remained high after adjusting for several 
factors such as lifestyle, socioeconomic differences and health status, the 
results of Study III suggest that there may be factors associated with the 
quality of physical care that explain a significant part of the excess mortality 
in people with NAP. There is evidence that the quality or intensity of care in 
cardiovascular disease and cancer is worse in NAP compared to the general 
population. For example, a Finnish study showed that coronary 
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revascularization was less frequently done to people with NAP who had CHD 
compared to other people diagnosed with CHD (Manderbacka et al., 2012). 
In addition, a recent study found increased cancer mortality in people with 
psychotic disorders which was also partly explained by poorer quality of 
treatment (Manderbacka et al., 2017). In the study by Manderbacka et al. 
(2017), the mortality gap in cancer mortality between people with psychotic 
disorders and those without mental illness increased over time, indicating 
that people with psychotic disorders are not benefiting from developments in 
cancer treatment as much as the general population. Similar findings of 
lower intensity or quality of care for people with chronic psychotic disorders 
have also been made concerning the treatment of cardiovascular disease, as 
reviewed by Laursen et al. (Laursen et al., 2014). 
In Study III, about 40% of the NAP group were smokers, and smoking 
was associated with increased risk of natural cause mortality. The increased 
risk has also been found in other studies examining mortality in serious 
mental illness (Dickerson et al., 2016; Tam et al., 2016). Smoking is more 
common in people with serious mental illness than in the general population, 
and according to a British report, smoking among people with psychiatric 
disorders has not declined at the same rate as in the general population 
(Harker and Cheeseman, 2016). The risk of natural cause mortality was 
reduced by antipsychotic medication use. In another Finnish study, 
antipsychotics were found to increase mortality in people who did not have a 
psychotic disorder but not in those with a psychotic disorder (Suvisaari et al., 
2013). Register-based studies have reported lower mortality risks in people 
with schizophrenia using antipsychotics compared to non-users (Crump et 
al., 2013b; Tiihonen et al., 2016; Torniainen et al., 2015). Antipsychotic use 
might reflect treatment adherence or insight and be therefore related to 
lower mortality. It is important to note that in Study III, the diagnoses of 
psychotic disorders were lifetime diagnoses and some of the disorders were 
in remission and no longer required medical treatment. There were also 
people who had dropped out of treatment and thus were no longer using 
antipsychotics. 
Inflammation measured by CRP levels increased the mortality risk in the 
total population sample of Study III, in agreement with findings from other 
studies (Emerging Risk Factors Collaboration et al., 2010), although CRP was 
not an independent risk factor for mortality in the population with NAP. A 
trend for higher CRP levels was observed in those with NAP who died during 
the follow-up (2.17mg/l vs. 1.47mg/l, p=0.17). The relatively small sample of 
people with NAP may have reduced the statistical power of the study to 
detect an effect for CRP on mortality. A study reported that levels of CRP 
over 3mg/l increased the mortality risk in people with schizophrenia, bipolar 
disorder and depression (n=3034) during a follow-up of up to 12 years (aHR 
1.56, 95% CI 1.02-2.38) (Horsdal et al., 2017). However, more studies are 




6.6 STRENGTHS AND LIMITATIONS 
6.6.1 STRENGTHS AND LIMITATIONS IN STUDIES I AND II 
The general strengths in Studies I and II include a reliable diagnostic 
process, utilizing structured diagnostic interview and all available 
information from medical records. Subjects with FEP were recruited from 
hospital and outpatient settings and they represent the population with FEP 
well. Controls were randomly recruited from the general population and 
matched for gender, age and region of residence to reduce sociodemographic 
bias. Laboratory measurements were conducted in a laboratory which is 
internationally accredited. The statistical method used in Study II to analyse 
the relationship between hs-CRP and anthropometric and clinical measures, 
mixed-effects regression analysis, accounts for the correlation of repeated 
observations in a longitudinal setting. Furthermore, in mixed-effects models, 
missing data resulting in different number of observations in different 
individuals does not prevent the usage of all the available data in the 
analysis.  
The limitations include the relatively large loss to follow-up among people 
with FEP. Attrition in longitudinal studies is common and hard to completely 
avoid. There were no statistically significant differences in baseline metabolic 
measures between those with data available throughout the follow-up and 
those who dropped out. The majority of the patients with FEP were already 
using antipsychotic medication at baseline. However, the median duration of 
medication at baseline was relatively short (22 days in Study II) and it did 
not result in baseline differences in BMI or waist circumference. Switches in 
antipsychotic medication during the follow-up were common, and thus it was 
not possible to analyse antipsychotic-specific effects on metabolic 
parameters. Furthermore, data on medications commonly used on an “as-
needed” basis, such as benzodiazepines and hypnotics, were not analysed. 
Antidepressant and mood stabilizing medications were used in addition to 
antipsychotic medication, but the prevalence of polypharmacy was lower 
than, for example, a Finnish study which reported that in recent-onset 
schizophrenia the prevalence of antipsychotic polypharmacy was 40%, and 
56% had previous use of antidepressants (Suokas et al., 2013). Further 
limitations are the use of HOMA as a measure of insulin resistance instead of 
a more accurate measurement, such as the oral minimal model method 
described in Chouinard et al. (2018). There are also more accurate methods 
to measure abdominal obesity than waist circumference (i.e. imaging 
methods), but these are not readily clinically available, and waist 
circumference has been shown to correlate well with abdominal fat mass 
(Pouliot et al., 1994). 
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6.6.2 STRENGTHS AND LIMITATIONS IN STUDY III 
Strengths of Study III include the large population sample, which represents 
well the total population, and reliable diagnostics using many sources of 
information (enabling the inclusion of individuals who had not actively 
sought treatment, as opposed to clinical or register-based studies) and the 
SCID-I interview. The final diagnoses were ascertained by multiple 
psychiatrists, increasing the diagnostic reliability. There was extensive 
information available on sociodemographic and lifestyle variables, and on 
chronic physical disease. The data on causes of death in Finland is reliable. 
Limitations of Study III include the relatively small number of cases with 
NAP, which resulted in wide confidence intervals in the analysis of mortality 
risk. Another limitation is that there were no data available from the follow-
up period on measures that potentially affect mortality, e.g. clinical 
information, sociodemographic variables and lifestyle. No deaths were 
observed in people with affective psychotic disorders, and thus the analysis 
was focused on NAP only. Other studies have found an increased mortality 
risk in mood disorders as well, although the risk may be lower than in 
schizophrenia (Crump et al., 2013a; Roshanaei-Moghaddam and Katon, 
2009). Previous studies in the same sample of affective psychoses as in Study 
III have shown that the risks of T2D, MetS or CHD were not increased 
compared to the general population (Suvisaari et al., 2010, 2008, 2007). The 
sample consisted of individuals older than 30 years of age which 
automatically excluded those who had committed suicide at a younger age 
and lowered the rate of suicides observed in this study. 
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7 CONCLUSIONS AND FUTURE RESEARCH 
7.1 MAIN CONCLUSIONS 
The aim of this study was to examine changes in weight, waist circumference, 
metabolic measures and low-grade inflammation in patients with FEP during 
the first year of treatment. Factors predicting weight gain and increase of 
waist circumference were investigated. In addition, this study aimed to 
examine factors associated with mortality in psychotic disorders.  
At the onset of FEP, some of the metabolic risk factors, i.e. insulin 
resistance, levels of total and LDL cholesterol and triglyceride levels, were 
already higher than in healthy controls of similar age, while BMI and waist 
circumference was similar across the groups. A significant increase in weight 
and waist circumference took place during the first year of treatment, 
accompanied by a rise in hs-CRP, indicating the development of chronic low-
grade inflammation. Insulin resistance and olanzapine medication at 
baseline were related to greater weight gain during the first year of treatment 
in FEP. Insulin resistance was also related to greater increase in waist 
circumference, suggesting that early insulin resistance during the treatment 
of FEP may mark an increased vulnerability for developing abdominal 
obesity. 
The increase in waist circumference observed in FEP, reflecting the 
development of abdominal obesity, was related to the increase in hs-CRP, a 
marker of low-grade inflammation. Thus, it seems that hs-CRP is not a 
reliable marker of progress or outcome in FEP, but it rather signals the pro-
inflammatory activity associated with increased visceral fat. 
This study showed that the mortality risk in NAP is increased 2-3-fold 
compared to the general population, a finding which is concordant with 
previous literature. The increased mortality risk was not completely 
explained by differences in socioeconomic factors, obesity, smoking, chronic 
physical conditions or inflammation, suggesting that there are other factors 
contributing to the risk that were not accounted for. For example, the quality 
of treatment of chronic physical conditions in people with psychotic 
disorders may be lower than average, and the risk of a delayed diagnosis of 
physical conditions may be higher. Smoking was associated with increased 
risk of natural cause mortality, demonstrating the importance of promoting 
smoking cessation and examining effective ways in helping people with 




7.2 CLINICAL IMPLICATIONS 
This study showed that young people with FEP are extremely vulnerable to 
the development of metabolic risk factors that result in significant increases 
in the risk for cardiovascular disease and diabetes. The weight gain, increase 
in waist circumference and low-grade inflammation in FEP that were 
observed in this study during the first year of treatment are alarming and 
rapid changes in young adults that are physically healthy at the onset of FEP. 
The increase in waist circumference was accompanied by increased low-
grade inflammation, an independent risk factor for cardiovascular disease 
and mortality. 
The findings highlight the importance of regular monitoring of physical 
health and the need for effective methods for prevention of physical 
complications in people with FEP. Weight, waist circumference, as well as 
lipid and glucose parameters should be regularly monitored to enable early 
prevention of metabolic adversities. Increased waist circumference is related 
to chronic low-grade inflammation, which provides another justification for 
frequent measurement of the waistline. Guidance and support in making 
healthy lifestyle modifications should be an integral part of the treatment of 
chronic psychiatric disorders. 
Early insulin resistance during the treatment of FEP may be a marker for 
increased risk of weight gain and abdominal obesity. However, more studies 
on the relationship between insulin resistance and the development of 
obesity in FEP are needed before any recommendation concerning the 
clinical use of measuring insulin resistance, in order to detect those with 
increased risk for adverse metabolic changes, can be made.  
Olanzapine was the most prescribed antipsychotic in FEP despite its high 
potential for weight gain. As is already recommended in some of the clinical 
care guidelines, antipsychotics other than olanzapine should be considered 
for first-line medication in FEP due to the adverse metabolic profile of 
olanzapine. As almost every antipsychotic is associated with significant 
metabolic risks, regular monitoring of weight, waist circumference and lipid 
and glucose parameters is essential to identify patients with the highest risk. 
Early intervention to reduce the metabolic risks in this highly vulnerable 
population is critical. It is important to note that although antipsychotics 
cause adverse metabolic changes, their use in the treatment of psychotic 
disorders is always indicated. Antipsychotics are effective in reducing 
psychotic symptoms and their use has also been associated with lower 
mortality in several studies compared to non-use. Also, in this study 
antipsychotic use was associated with lower natural cause mortality. 
This study showed that the increased mortality in NAP is partly due to 
factors that could be acted upon by improving the early detection of physical 
problems, and the quality of care of chronic physical illness. A review (De 
Hert et al., 2011a) looked into the barriers of treatment of physical 
comorbidities ranging from patient-specific factors (e.g. unawareness of 
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physical problems or late help-seeking due to cognitive problems, difficulties 
in adhering to the treatment of physical illness) to factors related to 
psychiatrists (e.g. lack of time/interest/knowledge of physical problems), 
other physicians (e.g. stigma, pessimistic view of the potential results of 
treatment) and overall health services (e.g. difficulties in accessing care, 
fragmentation of services among different providers, low resources in mental 
care). These barriers seem to remain stable. Both system and individual level 
actions are required to reduce the excess mortality. For example, facilitating 
collaboration between psychiatric and physical healthcare, improving access 
to physical care for people with SMI, as well as early monitoring of physical 
risk factors and interventions to reduce those risks are all essential. 
Advocating smoking cessation among people with psychotic disorders is 
probably the single most effective way to reduce the excess mortality of this 
population. There are effective pharmacological and psychosocial 
interventions for people with SMI who want to stop smoking (Aubin et al., 
2012). Their clinical use should be promoted. A significant proportion of 
people with mental illness are willing to quit smoking (Aubin et al., 2012), 
and this inclination should be endorsed by offering the means and support to 
succeed in quitting. 
7.3 FUTURE RESEARCH 
As yet, it is not possible to accurately predict which individuals with FEP are  
the highest risk for developing adverse metabolic changes. Future studies 
should examine clinically useful predictors for the development of abdominal 
obesity and other metabolic risks in FEP. Current findings in genetic risk 
factors for metabolic abnormalities have only a limited utility in identifying 
increased risk for metabolic abnormalities. In the future, constructing 
instruments with clinically significant predictive accuracy (e.g. genetic risk 
scores) would offer valuable tools to increase the identification of individuals 
with a high risk. Determining early thresholds for intervention to prevent 
further detrimental metabolic changes would be clinically useful. Further 
studies on early pharmacotherapy (e.g. metformin) to prevent antipsychotic-
induced weight gain are needed. 
Determining in detail the development of inflammatory processes in FEP 
with more refined measurements of immunological activity is warranted. 
Studies aiming to clarify the longitudinal course of immune activity in 
psychotic disorders by following individuals from high-risk states to full-
blown psychotic disorders are needed. The effects of risk factors for 
psychosis, lifestyle factors and antipsychotics on inflammatory activity 
should be further differentiated. In this study, hs-CRP was strongly linked to 
waist circumference and therefore it is not a potential marker for the risk or 
progress of psychotic disorder. However, future studies should examine in 
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detail the effects of chronic inflammation on the mortality risk in psychotic 
disorders. 
The mortality gap between people with SMI and the general population 
does not seem to be diminishing. Research is needed on the quality of 
treatment of physical disease in SMI. Future studies should address the 
questions of whether physical risk factors among people with SMI are 
identified and resolved with the timeliness and intensity required by 
guidelines of care, and what the reasons are underlying the probable lower 
quality of treatment of physical disease in people with SMI. Research on 
ways to facilitate the integration of care of chronic psychiatric and physical 
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